

# Interleukin-12 signaling drives Alzheimer's disease pathology through disrupting neuronal and oligodendrocyte homeostasis

Received: 12 April 2024

Accepted: 23 January 2025

Published online: 13 March 2025

 Check for updates


A list of authors and their affiliations appears at the end of the paper

Neuroinflammation including interleukin (IL)-12/IL-23-signaling is central to Alzheimer's disease (AD) pathology. Inhibition of p40, a subunit of IL-12/IL-23, attenuates pathology in AD-like mice; however, its signaling mechanism and expression pattern remained elusive. Here we show that IL-12 receptors are predominantly expressed in neurons and oligodendrocytes in AD-like APPPS1 mice and in patients with AD, whereas IL-23 receptor transcripts are barely detectable. Consistently, deletion of the IL-12 receptor in neuroectodermal cells ameliorated AD pathology in APPPS1 mice, whereas removal of IL-23 receptors had no effect. Genetic ablation of IL-12 signaling alone reverted the loss of mature oligodendrocytes, restored myelin homeostasis, rescued the amyloid- $\beta$ -dependent reduction of parvalbumin-positive interneurons and restored phagocytosis-related changes in microglia of APPPS1 mice. Furthermore, IL-12 protein expression was increased in human AD brains compared to healthy age-matched controls, and human oligodendrocyte-like cells responded profoundly to IL-12 stimulation. We conclude that oligodendroglial and neuronal IL-12 signaling, but not IL-23 signaling, are key in orchestrating AD-related neuroimmune crosstalk and that IL-12 represents an attractive therapeutic target in AD.

Pathological hallmarks of Alzheimer's disease (AD) are the faulty aggregation and deposition of amyloid- $\beta$  (A $\beta$ ) and tau proteins as well as pronounced neuroinflammation, which escalates with disease development. This process is primarily driven by microglia, the brain's intrinsic myeloid cells. A key inflammatory pathway in AD pathology is interleukin (IL)-12 and IL-23 signaling. IL-12 levels are increased in brain tissue and the cerebral spinal fluid (CSF) of patients with AD and of patients with mild cognitive impairment (MCI)<sup>1</sup>. IL-12 and IL-23 are heterodimers comprising the subunits p35 or p19, respectively, while sharing the common subunit p40 (IL12b). p40 can also form homodimers and binds either as homodimer or heterodimer to the IL-12 receptor subunit  $\beta$ 1 (IL12rb1) (Fig. 1a). IL-12-specific signaling is executed when, in combination with p40 actions, the IL-12 subunit p35 (IL12a) binds to the IL-12 receptor subunit  $\beta$ 2 (IL12rb2), whereas IL-23-specific signaling is induced in concert with p40 when the IL-23 subunit p19 (IL23a)

binds to the IL-23 receptor (IL23r)<sup>2,3</sup>. Each of these two IL-12 receptor subunits has been shown to occur as dimers/oligomers; the formation of these higher-order structures differing in their affinity to bind IL-12 is ligand independent, where IL-12R  $\beta$ 2 expression appears to be crucial for regulating IL-12 responsiveness<sup>4–6</sup>. We showed previously that inhibition of p40, which is produced by microglia AD-specifically, resulted in a substantial reduction of AD-related pathology in transgenic mouse models of amyloidosis, including a reduction in amyloid deposition and reversal of cognitive deficits<sup>7,8</sup>. Although innate immune cells and T lymphocytes are well known to respond to IL-12 and IL-23 in a peripheral—that is, a non-central nervous system (CNS) inflammatory—setting<sup>9</sup>, IL-12/IL-23 actions within the amyloidogenic AD brain are not understood: neither the exact cellular players are known nor whether IL-12 and/or IL-23 individually, or in concert, confer this AD-specific effect.

✉ e-mail: [rajewsky@mdc-berlin.de](mailto:rajewsky@mdc-berlin.de); [frank.heppner@charite.de](mailto:frank.heppner@charite.de)



**Fig. 1 | Deletion of IL-12-specific receptor subunit IL12RB2 results in reduction of amyloid burden.** **a**, p40 can form monodimers (IL-12p80) or heterodimers (IL-12p70) consisting of p35 and p40. IL-12p70 binds to the dimerized IL-12Rβ2 and IL-12Rβ1. IL-23, consisting of p19 and p40, binds to the receptor subunits IL-23Rα and IL-12Rβ1. The genes that encode the respective protein subunits are shown in matched color. This illustration was created in BioRender: Geesdorf, M. (2025) <https://BioRender.com/w20e262>. **b,c**, By crossbreeding either *Il12rb2<sup>fl/fl</sup>* or *Il23r<sup>fl/fl</sup>* mice to APPPS1 and to Nestin<sup>Cre</sup> animals, IL-12-specific or IL-23-specific receptor deletion was achieved in neuroectodermal cells of AD-like mice. This illustration was created in BioRender: Geesdorf, M. (2025) <https://BioRender.com/m33j769> and <https://BioRender.com/q27e982>. **d**, Proteins from total brains of 250-day-old APPPS1.Nestin<sup>Cre</sup>.*Il12rb2<sup>fl/fl</sup>* mice ( $n = 9$ ) and APPPS1 littermates expressing functional *Il12rb2* ( $n = 9$ ) were extracted based on their solubility and assessed for Aβ<sub>1-40</sub> and Aβ<sub>1-42</sub> in the soluble (TBS) and insoluble (Triton-X and SDS)

fractions using an electrochemiluminescence ELISA assay (Meso Scale). Aβ<sub>1-40</sub>:  $t = 3.062$ ,  $df = 16$ ,  $**P = 0.0075$  for the TBS fraction;  $t = 3.256$ ,  $df = 16$ ,  $**P = 0.0050$  for the TX fraction; and  $t = 2.034$ ,  $df = 11$ ,  $P = 0.668$  for the SDS fraction; Aβ<sub>1-42</sub>: unpaired  $t$ -tests,  $t = 0.5092$ ,  $df = 16$ ,  $P = 0.6175$  for the TBS fraction;  $t = 0.3554$ ,  $df = 16$ ,  $P = 0.7269$  for the TX fraction; and  $t = 1.627$ ,  $df = 11$ ,  $P = 0.1319$  for the SDS fraction. **e**, Aβ<sub>1-40</sub> and Aβ<sub>1-42</sub> levels in APPPS1.Nestin<sup>Cre</sup>.*Il23r<sup>fl/fl</sup>* mice ( $n = 9$ ) and APPPS1 littermates with functional IL-23 receptor subunit ( $n = 9$ ) upon similar workup as described in **d**; Aβ<sub>1-40</sub>:  $t = 0.7989$ ,  $df = 14$ ,  $P = 0.4377$  for the TBS fraction;  $t = 0.4474$ ,  $df = 16$ ,  $P = 0.6606$  for the TX fraction; and  $t = 1.393$ ,  $df = 15$ ,  $P = 0.1838$  for the SDS fraction; Aβ<sub>1-42</sub>:  $t = 1.710$ ,  $df = 16$ ,  $P = 0.1066$  for the TBS fraction;  $t = 0.1808$ ,  $df = 16$ ,  $P = 0.8588$  for the TX fraction; and  $t = 0.3960$ ,  $df = 16$ ,  $P = 0.69731$  for the SDS fraction. Data were analyzed as two-tailed unpaired  $t$ -test; bars represent mean ± s.e.m.  $df$ , degrees of freedom; NS, not significant.

## Results

### IL-12, not IL-23, is driving pathology in the amyloidogenic brain

To dissect whether IL-12 and/or IL-23 is driving the previously reported IL-12/IL-23/p40-mediated modulation of AD pathology in the amyloidogenic mouse brain<sup>7</sup> on a functional level, we bred AD-like APPPS1 to mice in which either the IL-12-specific receptor or the IL-23-specific receptor can be deleted conditionally, namely *Il12rb2<sup>fl/fl</sup>* or *Il23r<sup>fl/fl</sup>* mice, resulting in APPPS1.*Il12rb2<sup>fl/fl</sup>* or in APPPS1.*Il23r<sup>fl/fl</sup>* mice. To identify those CNS cells that harbor the respective receptors, we crossed the aforementioned double transgenic mice to Nestin<sup>Cre</sup> reporter mice, thus enabling excision of the floxed gene segment encoding either the IL-12 receptor or the IL-23 receptor, through Cre-mediated recombination in cells from the neuroectodermal lineage—that is, in astrocytes, oligodendrocytes and neurons (Fig. 1b,c). Measuring the amount of amyloid burden in solubility-based brain protein extracts, we observed a significant (biochemically Aβ<sub>1-40</sub>-dominant) reduction of Aβ burden in APPPS1.

Nestin<sup>Cre</sup>.*Il12rb2<sup>fl/fl</sup>* mice lacking the IL-12-specific receptor gene *Il12rb2* when compared to APPPS1 mice harboring the IL-12-specific receptor subunit β2 (Fig. 1d). In contrast, deleting IL-23 receptor in a similar fashion in neuroectodermal cells in APPPS1.Nestin<sup>Cre</sup>.*Il23r<sup>fl/fl</sup>* mice did not result in changes in Aβ<sub>1-40</sub> or Aβ<sub>1-42</sub> in all protein fractions—that is, soluble TBS, insoluble Triton-X and SDS fractions contained Aβ<sub>1-40</sub> and Aβ<sub>1-42</sub> levels identical to APPPS1 littermates harboring the IL-23 receptor in the neuroectoderm (Fig. 1e). These experiments showed that exclusive deletion of IL-12 signaling, but not of IL-23, recapitulated the reduction by approximately 50% in Aβ burden in APPPS1.*Il12b<sup>-/-</sup>* mice (lacking IL-12 and IL-23 in concert), as previously described by us<sup>7</sup>.

### Transcriptional regulation of IL-12/23 in the human CNS

To assess whether the molecular repertoire of IL-12/23 signaling is not only present in mice but also in the human CNS, and to bypass the lack of reliable detection tools, such as antibodies to most components

of these multi-subunit cytokines and their receptors, we examined publicly available single-nucleus transcriptome datasets provided by the Allen Brain Map Atlas derived from postmortem human primary motor cortex tissue. Here, we found that *IL12RB1* and, even more strongly, *IL12RB2* transcripts were expressed by neurons and somewhat weaker by oligodendrocytes, whereas *IL23R* expression was rather faint<sup>10</sup> (Extended Data Fig. 1a–c).

### Neurons and oligodendrocytes are IL-12 target cells

We next aimed to gain an unbiased understanding of IL-12 signaling in the amyloidogenic environment of the hippocampus, a brain area that is central for executing cognitive functions and known to be affected in AD pathology<sup>11</sup>. We characterized the transcriptional signature of individual hippocampi dissected from 250-day-old A $\beta$ -overexpressing APPPS1 or APPPS1.*IL12b*<sup>-/-</sup> as well as wild-type (WT) littermate control animals by single-nucleus RNA sequencing (snRNA-seq). Three independent experiments (Fig. 2a)—after removal of low-quality nuclei and doublets—yielded a total of 82,298 nuclei expressing an average of 1,412 genes and 2,421 transcripts (defined as unique molecular identifiers (UMIs)) (Extended Data Fig. 1d–h). Roughly 86% of all captured transcripts were protein-coding, whereas 13% comprised long non-coding RNAs (lncRNAs), many of which were cell type specific (Extended Data Fig. 1i–k). Cell types in the hippocampus encompassed excitatory and inhibitory neurons, Cajal Retzius cells, choroid plexus cells, astrocytes, microglia, macrophages, oligodendrocytes, oligodendrocyte progenitor cells (OPCs), fibroblasts and vascular cells. Doublets were identified in 5% of all nuclei and in eight of 44 clusters (Extended Data Fig. 1f–h), and those clusters harboring more than 50% of doublets were removed from further analysis.

Unsupervised clustering followed by uniform manifold approximation and projection (UMAP) for visualization revealed 37 clusters that were assigned to various neuronal, glial and other cell types based on the expression of known marker genes (Fig. 2b and Extended Data Fig. 1j)<sup>12,13</sup>. We identified 18 clusters of excitatory neurons, which were assigned to the anatomical region of the dentate gyrus, the cornu ammonis (CA) 1, CA2/CA3 and the subiculum; three clusters of inhibitory neurons; seven clusters of glial cells (microglia, astrocytes, oligodendrocytes and OPCs); and a small cluster with features of Cajal Retzius cells. Non-neural cells comprised myeloid cells, such as peripheral macrophages (distinct from CNS-resident microglia) and small clusters of fibroblasts and choroid plexus and endothelial cells. The hippocampus as a particularly neuron-rich brain region revealed a majority of neurons among the recovered nuclei (60% combined of excitatory and inhibitory neurons), followed by glia (37% combining microglia, oligodendrocytes, astrocytes and OPCs) (Extended Data Fig. 1k). These cell type proportions are consistent with the cell type composition of the mouse hippocampus—for example, as determined by the Blue

Brain Cell Atlas (68% neuronal versus 32% of glial cells) (Extended Data Fig. 1l)<sup>14,15</sup>. The snRNA-seq data from all three independent biological replicates were superimposable—that is, showed no major batch effects and justified data aggregation without resorting to batch correction or alignment procedures (Extended Data Fig. 2a–d). This indicates that an  $n = 3$  per genotype in our hands is a sufficient group size for downstream analyses. Furthermore, gene expression levels correlated between hippocampal snRNA-seq and bulk RNA-seq data ( $R \geq 0.75$ ), indicating that the single-nucleus data reflect the transcript composition of the intact tissue (Extended Data Fig. 3a).


A major pathological hallmark of AD is a substantial phenotypic alteration and proliferation of CNS-resident microglia and astrocytes. This is reflected by distinct transcriptome profiles of WT versus APPPS1 mice including an AD-specific upregulation of microglial pro-inflammatory genes, such as *IL12b* and *Clec7a* (Extended Data Fig. 3b,c)—a phenotype that was largely reverted upon deleting *IL12b* in APPPS1 mice (Extended Data Fig. 3d). Close-ups of the astrocyte populations in both AD-related genotypes, namely in APPPS1 and APPPS1.*IL12b*<sup>-/-</sup> mice, showed an equally A $\beta$ -reactive, *Gfap*-enriched inflammatory astrocyte cluster, suggesting that the lack or presence of p40 does not alter the astrocytic phenotype in the amyloidogenic CNS (Extended Data Fig. 3e–h). Interestingly, we observed a substantial reduction of oligodendrocytes, but not of their progenitors, in APPPS1 mice compared to WT mice (Fig. 2c). Notably, the AD-specific decrease in oligodendrocytes was rescued in APPPS1.*IL12b*<sup>-/-</sup> mice. Cell type deconvolution of bulk RNA-seq data<sup>16</sup> and quantification of oligodendrocytes in brain tissue sections by means of immunohistochemistry confirmed these findings (Fig. 2d–f and Extended Data Fig. 3i,j). Olig2<sup>+</sup> cells were significantly reduced in the hippocampus of APPPS1 mice, and this reduction was reversed to the WT level in APPPS1.*IL12b*<sup>-/-</sup> mice (Fig. 2f). We further quantified CCI<sup>+</sup>/Olig2<sup>+</sup> mature oligodendrocytes in the hippocampus, cortex and corpus callosum of APPPS1, WT and APPPS1.*IL12b*<sup>-/-</sup> mice. In each of these areas, mature CCI<sup>+</sup>/Olig2<sup>+</sup> oligodendrocytes were significantly decreased in APPPS1 versus WT mice, whereas they were unaltered compared to WT in APPPS1.*IL12b*<sup>-/-</sup> mice (Fig. 2g–i). In contrast, overall Olig2<sup>+</sup> cells were not substantially changed in numbers in the cortex and corpus callosum of these mice. These data speak in favor of an IL-12-dependent loss of mature oligodendrocytes in the amyloid-rich brain, which can be rescued by interfering with IL-12 signaling.


To assess transcript expression of both IL-12 receptor subunits and of IL-23 receptor particularly in neurons and oligodendrocytes, we determined the cell-type-specific expression of IL-12/IL-23-associated transcripts within our snRNA-seq data. *IL12rb1* was mostly expressed in oligodendrocytes (Fig. 3a), whereas *IL12rb2* was more generally distributed across several cell types while clearly pronounced in neurons and oligodendrocytes (Fig. 3b). Transcripts encoding the IL-23

### Fig. 2 | IL-12/IL-23 signaling reduces hippocampal oligodendrocytes in a mouse model of AD. a

Experimental outline. Isolated nuclei from hippocampi of 250-day-old animals ( $n = 3$  per genotype), purified by FACS and used for snRNA-seq. Bulk RNA-seq libraries were prepared from RNA isolated of hippocampi ( $n = 3$  per genotype). If not stated otherwise, figures reflect results from snRNA-seq. Illustration was created in BioRender: Geesdorf, M. (2025) <https://BioRender.com/a60r345>. b, UMAP plot showing 37 hippocampal cell clusters representing combined snRNA-seq data from three biological replicates per genotype. Cell types were assigned based on known markers. c, Cell type proportions in hippocampal samples across all three genotypes. Each dot represents one biological replicate ( $n = 3$ ). One-way ANOVA with Holm–Bonferroni  $P$  value adjustment,  $df = 2$ ,  $F = 1.945$  for excitatory neurons,  $F = 0.563$  for inhibitory neurons,  $F = 0.116$  for astrocytes,  $F = 8.279$  for microglia,  $F = 7.720$  for oligodendrocytes and  $F = 2.245$  for OPCs; boxplots show middle, median; lower hinge, 25% quantile; upper hinge, 75% quantile; upper/lower whisker, largest/smallest observation less/greater than or equal to upper/lower hinge  $\pm 1.5 \times$  IQR. d, Mouse brain sections stained with DAPI (blue) and for

Olig2 (red). The hippocampal outline was defined as the ROI (dashed white line) for quantifying Olig2<sup>+</sup> cells. Scale bar, 100  $\mu$ m. e, Representative zoomed-in images of brain tissue from WT, APPPS1 and APPPS1.*IL12b*<sup>-/-</sup> mice showing Olig2<sup>+</sup> cells. f, Quantification of Olig2<sup>+</sup> cells normalized to DAPI<sup>+</sup> cells in hippocampal regions ( $n = 5$  per genotype with 3–6 sections per animal). One-way ANOVA with Tukey's multiple comparison test,  $df = 2$ ,  $F = 6.270$ ,  $*P = 0.0137$ . Each symbol represents one mouse. Bars represent mean  $\pm$  s.e.m. g–i, Quantification of CCI<sup>+</sup>/Olig2<sup>+</sup> mature oligodendrocytes in cortex, corpus callosum and CA1.  $n = 4$  for WT and APPPS1 and  $n = 3$  for APPPS1.*IL12b*<sup>-/-</sup> mice. Scale bar, 100  $\mu$ m. g–i, One-way ANOVA with Tukey's multiple comparison test on WT (mean = 91.67  $\pm$  s.e.m.), APPPS1 (mean = 77.99  $\pm$  s.e.m.) and APPPS1.*IL12b*<sup>-/-</sup> (mean = 94.87  $\pm$  s.e.m.),  $df = 2$ ,  $F = 0.8176$ ,  $*P = 0.0116$  (g); WT (mean = 95.85  $\pm$  s.e.m.), APPPS1 (mean = 89.05  $\pm$  s.e.m.) and APPPS1.*IL12b*<sup>-/-</sup> (mean = 95.09  $\pm$  s.e.m.),  $df = 2$ ,  $F = 7.132$ ,  $*P = 0.0167$  (h); WT (mean = 83.52  $\pm$  s.e.m.), APPPS1 (mean = 71.51  $\pm$  s.e.m.) and APPPS1.*IL12b*<sup>-/-</sup> (mean = 81.31  $\pm$  s.e.m.),  $df = 2$ ,  $F = 10.04$ ,  $*P = 0.0066$ . (i). df, degrees of freedom; IQR, interquartile range; NS, not significant.





**Fig. 3 | IL-12 and IL-23 receptor transcript expression and IL-12 protein levels in mouse and/or human postmortem brain tissue.** **a**, *Il12rb1*, coding for IL-12 receptor subunit  $\beta 1$ , is equally expressed across all three mouse genotypes (as indicated) and occurs most pronouncedly in oligodendrocytes. Violin plot showing captured *Il12rb1* transcripts across cell types. **b**, *Il12rb2*, coding for IL-12 receptor subunit  $\beta 2$ , is strongly expressed in neurons and, to a lesser extent, in microglia, oligodendrocytes, OPCs and astrocytes. Violin plot showing captured *Il12rb2* transcripts across cell types. **c**, *Il23r* transcripts were only barely expressed in the aged mouse hippocampus. Violin plot showing captured *Il23r* transcripts across cell types. **d**, smFISH on brain tissue of APPS1 mice revealed *Il12rb1* mRNA<sup>+</sup> puncta (pink) in oligodendrocytes (marked by expression of *Sox10* mRNAs (blue)); microglia expressing *Tmem119* and *Sall1* are marked by yellow puncta; DAPI shown in gray depicts cell nuclei. **e**, *Il12rb2* mRNA<sup>+</sup> puncta (pink)

in neurons (marked by *Map2* and *NeuN* mRNAs (yellow)); astrocytes expressing *Aldh1l1*, *Gfap* and *Glast* are marked in blue; DAPI shown in gray depicts cell nuclei. Signals specific to *Il23r* mRNA were not detectable. Scale bar, 25  $\mu$ m. **f**, Human postmortem hippocampal brain tissue from individuals without dementia ( $n = 4$ ) and from patients with AD ( $n = 3$ ). qPCR results showing *IL12RB2* and *IL23R* gene expression in bulk human hippocampal tissue, \*\*\*\* $P = 1.678 \times 10^{-9}$ ,  $t = 16.14$ ,  $df = 12$ . Statistical analysis using two-tailed unpaired Student's *t*-test. **g–i**, IL-12p70 protein as measured by ELISA in soluble tissue fraction of frontal cortex from age-matched non-AD controls ( $n = 14$ ) and from patients with AD ( $n = 44$ ). Statistical analysis using two-sided Mann-Whitney test for age-matched healthy controls (median =  $0.5395 \pm$  s.e.m.) and for patients with AD (median =  $0.7946 \pm$  s.e.m.), \* $P = 0.0316$ ; Braak II–III:  $P = 0.8411$ , Braak V–VI: \* $P = 0.0117$ .  $df$ , degrees of freedom; NS, not significant.

receptor (*Il23r*) were barely detectable in the hippocampus and absent in oligodendrocytes (Fig. 3c), suggesting that IL-23 is not involved in mediating the p40-dependent changes described in APPS1 mice<sup>7</sup>. To visualize transcript expression, we applied single-molecule RNA fluorescence in situ hybridization (smFISH) on aged mouse brain tissue, where each fluorescent spot corresponds to one single RNA transcript. In line with our snRNA-seq data (Fig. 3a), we found *Il12rb1* transcripts in *Sox10*<sup>+</sup> oligodendrocytes and *Il12rb2* transcripts in

*Rbfox3*<sup>+</sup>/*Tubb3*<sup>+</sup> neurons, whereas *Il23r* signals were not detectable in either cell type (Fig. 3d,e).

qRT-PCR of postmortem hippocampal brain tissue from non-demented controls or patients with AD (Fig. 3f and Supplementary Data Table 1) corroborated the mouse and human data: irrespective of AD pathology, we found *IL12RB2* transcripts specific for the IL-12 receptor to be expressed in human brains, whereas transcripts for the IL-23 receptor were lacking. As the receptor expression abundance did

not change with disease status, we next wondered whether the ligand IL-12p70 does. Using human postmortem brain tissue of 44 AD cases and 14 age-matched non-demented control cases, we found IL-12p70 protein to be elevated in AD brains (Fig. 3g). Of note, IL-12p70 protein expression was mainly pronounced in AD cases with higher Braak stages (Braak stages V–VI) (Fig. 3h,i).

This set of experiments revealed that IL-12 signaling (1) substantially affects mature oligodendrocytes in the amyloidogenic mouse brain and (2) preferentially acts through an AD-specific upregulation of its ligand IL-12.

### Mature oligodendrocytes are substantially impacted by IL-12 signaling

By investigating the most highly variable genes in the oligodendrocyte lineage and all expressed transcription factors in our snRNA-seq dataset, we observed a differential trajectory of oligodendrocyte clusters resembling various stages of differentiation or maturation (Fig. 4a,b). A detailed analysis revealed that preferentially mature oligodendrocytes, namely myelin-forming oligodendrocytes (MFOLs) and mature oligodendrocytes (MOLs), accounted for the strong reduction of these cell populations in APPPS1 mice (Fig. 4c,d). To assess whether the reduced number of mature oligodendrocytes might be the result of a dysregulation in OPC maturation in APPPS1 mice, we investigated the genetic profile of the various maturation states of oligodendrocytes (Extended Data Fig. 4a–c). Pseudotime analyses of genes involved in regulating oligodendrocyte differentiation showed no difference between APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> mice across all oligodendrocyte maturation states (Extended Data Fig. 4d–g). However, Gene Ontology (GO) analysis in OPCs revealed enriched genes involved in myelination (*Clu* and *Olig2*) and developmental differentiation (*Plcb1*, *Kcnma1* and *Sez6l*) in APPPS1 versus APPPS1.*Il12b*<sup>-/-</sup> mice, indicating compensatory processes in OPCs directed at replacing dysfunctional and/or lost mature oligodendrocytes (Extended Data Fig. 5a). Given that the concept of OPC dynamics, balancing oligodendrocyte cell survival and cell death primarily is known from CNS development, it may well apply and re-appear in the context of CNS diseases affecting myelin and/or mature oligodendrocytes. In MFOLs of APPPS1 mice, genes involved in cellular responses to oxidative stress (*Slc8a1*, *Ptprk* and *Oxr1*) and in programmed cell death (*Elmo1*, *Oxr1*, *Hif3a*, *Gli2*, *Eya4* and *Cst3*) were upregulated when compared to MFOLs derived from APPPS1.*Il12b*<sup>-/-</sup> mice. Similarly, MOLs of APPPS1 mice showed an upregulation of genes inhibiting programmed cell death (*Sox10*, *Gli2* and *Sgk3*) compared to their counterparts derived from APPPS1.*Il12b*<sup>-/-</sup> mice (Extended Data Fig. 5b), indicating that IL-12 signaling is capable of regulating oligodendrocyte homeostasis by mediating the balance between cell death and survival.

To assess oligodendroglial myelin sheath-forming capacity in relation to AD pathology and IL-12 signaling, we analyzed myelin integrity

by means of immunohistochemistry and electron microscopy. Quantification of myelin basic protein (MBP) as an essential product of MFOLs revealed reduced MBP immunoreactivity in APPPS1 versus WT mice in the corpus callosum. In contrast, levels were unaltered in APPPS1.*Il12b*<sup>-/-</sup> versus WT mice (Fig. 4e,f). In the somatosensory cortex, MBP coverage was similar across all genotypes, most likely due to the relatively small amount of myelination in this brain area (Extended Data Fig. 5c,d). Using electron microscopy, we analyzed the ultrastructure of myelin in the hippocampus of APPPS1 mice lacking or harboring IL-12 signaling. In line with our previous findings, the proportion of the inner axonal diameter to the total outer myelin (depicted by the g-ratio) was higher in APPPS1 mice (indicating thinner myelin sheaths) compared to WT mice, whereas APPPS1.*Il12b*<sup>-/-</sup> mouse myelin appeared similar to WT myelin (Fig. 4g–i). The rather high g-ratio observed across all genotypes is likely due to the old age of the animals investigated, as aging itself leads to myelin swelling, fragmentation and delamination<sup>17–19</sup>.

Moreover, lipid profiles generated by untargeted lipidomics of myelin-enriched corpus callosum tissue were clearly distinct in APPPS1 mice compared to WT mice at 120 days and 250 days of age, reflecting the observed myelin pathology. This AD-specific phenotype was partially rescued in 250-day-old APPPS1.*Il12b*<sup>-/-</sup> mice, indicating that the AD-specific alterations of the CNS lipidome are partially restored upon interference with IL-12 signaling (Fig. 4j–m).

To confirm the direct negative impact of IL-12p70 and IL-12p80 signaling on oligodendrocyte and neuronal homeostasis, we administered IL-12p70 and IL-12p80 to primary murine co-cultures consisting of neurons, microglia, astrocytes and oligodendrocytes; the latter typically form compact myelin sheaths around neurofilament-positive axons<sup>20</sup> (Fig. 5a). This treatment reduced the density of MBP and neurofilament compared to vehicle-control-stimulated cultures (Fig. 5b–d), impacted overall cell survival as measured by cell numbers and enhanced cleaved caspase-3 immunoreactivity (Fig. 5e,f) and was mediated by phosphorylated STAT4 (Fig. 5g).


To test whether human oligodendrocytes have, in principle, the capacity to react to IL-12 on a functional level, we differentiated human oligodendrocyte-like cells derived from the oligodendroglioma cell line SCC163 cells in vitro<sup>21</sup> (Extended Data Fig. 5e,f) and treated these cells with IL-12p70, IL-12p80 or IL-23. Upon maturation, human oligodendrocyte-like cells released an array of pro-inflammatory factors, such as TNF- $\beta$ , IL-1a and IL-17, when exposed to IL-12, of which IL-12p80 induced the strongest response (Extended Data Fig. 5g,h), whereas there was almost no response to IL-23 (Extended Data Fig. 5i).

In conclusion, these data show that myelination is substantially impaired in the amyloid-rich mouse brain in an IL-12-dependent fashion—a phenotype that can be rescued in vivo through the deletion of IL-12 signaling—whereas mouse oligodendrocytes and human and oligodendrocyte-like cells react profoundly to IL-12 treatment in vitro.

### Fig. 4 | Reduced number of mature oligodendrocytes in the amyloid-carrying hippocampus of AD-like mice exhibit compromised myelin ensheathment.

**a**, Feature plots highlighting markers that characterize known oligodendrocyte maturation states. **b**, Pseudotemporal ordering of oligodendrocytes revealed differentiation along the known maturation trajectory from OPC via NFOL to MFOL and MOL. **c**, Cell proportion density along the pseudotime suggests a decrease of more mature oligodendrocytes in the amyloid-carrying APPPS1 mouse hippocampus. **d**, Reduction of oligodendrocytes reaches statistical significance at the stage of MFOL and MOL and is rescued by the absence of IL-12.  $n = 3$  per genotype,  $df = 2$ ,  $F = 2.067$  for OPC,  $F = 1.443$  for NFOL,  $F = 6.184$  for MFOL and  $F = 6.705$  for MOL; statistical analysis done by one-way ANOVA with Holm–Bonferroni  $P$  value adjustment; boxplots show middle, median; lower hinge, 25% quantile; upper hinge, 75% quantile; upper/lower whisker, largest/smallest observation less/greater than or equal to upper/lower hinge  $\pm 1.5 \times$  IQR. **e**, Representative immunohistochemical MBP staining of corpus callosum from 250-day-old WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> mouse brains. **f**, Analysis of

MBP mean gray value, normalized by DAPI mean gray value. One-way ANOVA with Tukey's multiple comparison test,  $df = 2$ ,  $F = 7.185$ ,  $**P = 0.0051$ . Each symbol represents one mouse. Bars represent mean  $\pm$  s.e.m. **g**, Representative ultrastructural images depicting the hippocampal alveus of 250-day-old WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> mice. Scale bar, 2  $\mu$ m. **h**, Analysis of g-ratio depicting the proportion of the inner axonal diameter to the total outer myelin, Kruskal–Wallis chi-squared = 126.83,  $df = 2$ ,  $P < 2.2 \times 10^{-16}$ . **i**, Myelin sheath thickness of  $n = 3$  mice per genotype, Kruskal–Wallis chi-squared = 23.244,  $df = 2$ ,  $P = 8.966 \times 10^{-6}$ . Electron microscopy images were analyzed by Kruskal–Wallis rank-sum test with Bonferroni correction for multiple testing. Bars represent mean  $\pm$  s.e.m. **j**, PLS-DA plot of lipidomics data of 120-day-old WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> white matter. **k**, Heatmap of lipidomics data of 120-day-old WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> white matter. **l**, PLS-DA plot of lipidomics data of 250-day-old WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> white matter. **m**, Heatmap of lipidomics data of 250-day-old WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> white matter. **df**, degrees of freedom; IQR, interquartile range; NS, not significant.




## IL-12 signaling affects neuronal homeostasis in AD-like mice

We previously showed that pharmacological inhibition or genetic deletion of IL-12/IL-23 signaling reversed cognitive deficits in aged APPPS1 mice<sup>7</sup>, suggesting that—based on the herein-presented identification that IL-12, but not IL-23, is key in AD-associated IL-12/IL-23 signaling—neuronal homeostasis is affected by IL-12 signaling. Approximately 10–15% of neurons in the hippocampus are GABAergic inhibitory interneurons<sup>22</sup>, which are known to play a crucial role in determining and regulating cortical circuit function. Cognitive decline in patients with AD, at least in part, can be attributed to neuronal hyperexcitability caused by GABA inhibitory interneuron dysfunction in the hippocampus<sup>23</sup>. Notably, by means of immunohistochemical analyses of brain tissue, we found parvalbumin-positive (PV<sup>+</sup>) interneurons in the hippocampal CA1 region of APPPS1 mice to be decreased when compared to WT littermates (Fig. 6a). Strikingly, this reduction in PV<sup>+</sup> interneurons was rescued in the hippocampus and the cortex of APPPS1.*Il12b*<sup>-/-</sup> mice (Fig. 6b).

When investigating the effects of IL-12 signaling on neurons at the transcriptome level, we also found a reduced number of neurons within the subiculum in AD-like APPPS1 mice compared to WT littermates (which did not reach significance) as well as alterations in the gene expression of subicular neurons of APPPS1 mice lacking *Il12b* compared to APPPS1 mice with functional IL-12 signaling (Extended Data Fig. 6a,b). Affected genes are involved in pathways impacting hippocampal memory and synaptic plasticity, such as *ErbB4* and *Rarb*<sup>24–26</sup>. In addition to seeing some differential regulation of genes involved in ion homeostasis, we also found an upregulation of genes implicated in dendrite development (*Dab1*, *Fat3*, *Fezf2*, *Fmn1*, *Hecw2*, *Klhl1*, *Map1b*, *Nedd3l*, *Sez6* and *Ss181*) in APPPS1.*Il12b*<sup>-/-</sup> mice compared to APPPS1 mice, suggesting IL-12-dependent enhanced compensatory efforts aimed at regenerating neuronal homeostasis in the AD microenvironment (Fig. 6c).


To gain insights into the cell–cell communication between different neuronal subtypes, we applied CellPhoneDB, a publicly available repository of distinct receptors, ligands and their interactions, to provide correlative relations of co-expressed receptor–ligand pairs derived from single-cell RNA-seq data<sup>27</sup>. We observed a region-specific IL-12-dependent alteration in the receptor–ligand pairing of neuropilin (*Nrp1*, *Nrp2* and vascular endothelial growth factor A (*Vegfa*) as well as *Ephb2* and *Grin2b* in excitatory and inhibitory neurons in APPPS1 mice, in subiculum, dentate gyrus and CA2/CA3 (Fig. 6d). *Nrp1* and *Nrp2*

serve as co-receptors for VEGF receptors and support neuronal guidance as well as dendritic growth and branching in the adult brain<sup>28,29</sup>. Of note, CellPhoneDB-based analyses revealed a reduced *Nrg1–ErbB3* interaction in newly formed oligodendrocytes (NFOLs) in the dentate gyrus, CA1 and in the subiculum of APPPS1 compared to WT mice and was rescued in APPPS1.*Il12b*<sup>-/-</sup> mice, reaching WT levels (Fig. 6e). This signaling affects oligodendrocyte survival in vitro<sup>30</sup> but, so far, has been claimed to be involved only in normal myelination in vivo in the peripheral nervous system by gain of function<sup>31</sup>. Moreover, *Nrg2–ErbB4* was reduced in dentate gyrus-derived MOLs of APPPS1 mice and reverted to WT levels in APPPS1.*Il12b*<sup>-/-</sup> mice lacking functional *Il12b* signaling. These data indicate that IL-12 signaling-dependent perturbations in the transcriptional profile of neurons (ultimately leading to functional dysregulation) might be mediated either through binding of IL-12 to its receptor directly on the neuronal cell surface or through IL-12 affecting oligodendrocytes and leading to an alteration in their trophic support of neurons<sup>32</sup> or a combination thereof.



**Fig. 5** | IL-12p70 or IL-12p80 stimulation of murine embryonic primary myelinating culture results in reduced neurofilament and myelination. **a**, Cell culture from E13 murine spinal cords treated with either IL-12p70 or IL-12p80 from DIV12 to DIV30. **b**, Immunocytochemistry from DIV30: blue, DAPI; white, MBP; pink, neurofilament. Scale bar, 100  $\mu$ m. **c**, Quantification of neurofilament-covered area (%), biological replicates of vehicle-treated and IL-12p80-treated ( $n = 6$ ) and IL-12p70-treated ( $n = 3$ ) cell cultures, one-way ANOVA for vehicle control (mean = 6.780  $\pm$  s.e.m.), IL-12p70 (mean = 1.513  $\pm$  s.e.m.) and IL-12p80 (mean = 1.368  $\pm$  s.e.m.),  $df = 2$ ,  $F = 13.09$ ,  $P = 0.0010$ . **d**, Quantification of MBP-covered area (%), biological replicates of vehicle-treated and IL-12p80-treated ( $n = 6$ ) and IL-12p70-treated ( $n = 3$ ) cell cultures, one-way ANOVA for vehicle control (mean = 6.682  $\pm$  s.e.m.), IL-12p70 (mean = 1.237  $\pm$  s.e.m.) and IL-12p80 (mean = 1.295  $\pm$  s.e.m.),  $df = 2$ ,  $F = 52.70$ ,  $P < 0.0001$ . **e**, DAPI<sup>+</sup> cell count, biological replicates of vehicle-treated and IL-12p80-treated ( $n = 6$ ) and IL-12p70-treated ( $n = 3$ ) cell cultures, one-way ANOVA for vehicle control (mean = 227.0  $\pm$  s.e.m.), IL-12p70 (mean = 104.0  $\pm$  s.e.m.) and IL-12p80 (mean = 110.2  $\pm$  s.e.m.),  $df = 2$ ,  $F = 19.80$ ,  $P = 0.0002$ . **f**, Quantification of apoptotic cells (%), biological replicates of vehicle-treated and IL-12p80-treated ( $n = 6$ ) and IL-12p70-treated ( $n = 3$ ) cell cultures, Kruskal–Wallis test for vehicle control (mean = 3.832  $\pm$  s.e.m.), IL-12p70 (mean = 7.333  $\pm$  s.e.m.) and IL-12p80 (mean = 12.50  $\pm$  s.e.m.), Kruskal–Wallis statistic = 11.35,  $P < 0.0001$ . **g**, Actin and pSTAT4 western blot analysis of IL-12p70-treated, IL-12p80-treated and non-treated primary oligodendrocytes; non-treated: 1.0 (left), IL-12p70-stimulated: 1.87 (center) and IL-12p80: 1.33 (right); pSTAT4 signal normalized to actin signal.  $df$ , degrees of freedom.





**Fig. 6 | IL-12 signaling leads to transcriptional changes in mouse hippocampal and cortical neurons. a**, Representative images of PV<sup>+</sup> interneurons in the cortex and hippocampus of APPPS1.I112b<sup>-/-</sup> mice. **b**, Quantification of PV<sup>+</sup> interneurons comparing WT (cortex mean = 23.49 ± s.e.m.; CA1 mean = 5.868 ± s.e.m.), APPPS1 (cortex mean = 17.67 ± s.e.m.; CA1 mean = 4.653 ± s.e.m.) and APPPS1.I112b<sup>-/-</sup> mice (cortex mean = 24.66 ± s.e.m.; CA1 mean = 6.324 ± s.e.m.) ( $n = 8$  per genotype), one-way ANOVA,  $df = 2$ ,  $F = 4.620$ ,  $P = 0.232$  for CA1 and one-way ANOVA,  $df = 2$ ,  $F = 15.68$ ,  $P < 0.0001$  for cortex. **c**, GO analysis of genes upregulated in subiculum

comparing APPPS1 versus WT mice, APPPS1.I112b<sup>-/-</sup> versus WT mice, APPPS1 versus APPPS1.I112b<sup>-/-</sup> mice and APPPS1.I112b<sup>-/-</sup> versus APPPS1 mice. **d,e**, Using CellPhoneDB, dot plot showing the predicted receptor–ligand interactions between neuronal cell types (**d**) and oligodendrocytes (**e**) in WT, APPPS1 and APPPS1.I112b<sup>-/-</sup> mice.  $P$  values are indicated by the circle size, and means of the average expression level are color coded. *df*, degrees of freedom; exp, expression.

### Altered microglial function in AD-like APPPS1.I112b<sup>-/-</sup> mice

Because microglia have a strong impact on neuroinflammation and AD pathology, we assessed transcriptional changes in microglia from APPPS1 mice with and without genetic ablation of *I112b*. We observed two microglia clusters (Fig. 7a), one of which was prominent in both APPPS1 and APPPS1.I112b<sup>-/-</sup> mice—that is, AD specific but virtually absent in age-matched WT mouse brains. Differential gene expression analyses between these two microglia clusters showed upregulation in IL-12-competent and IL-12-deficient APPPS1 mice of few

*Trem2*-independent (*ApoE*) and many *Trem2*-dependent (*Ank*, *Csf1*, *Clec7a*, *Axl*, *Spp1*, *Itgax* and *Igf1*) genes<sup>33</sup>, including lipid metabolism and phagocytic pathways (*Lpl*, *Cst7* and *Cd9*) as well as the downregulation of homeostatic microglia genes (*P2ry12*, *Cx3cr1* and *Tmem119*) (Fig. 7b). This gene expression signature showed strong similarities to the previously described signature from disease-associated microglia (DAM), which is linked to an altered microglial activation state in another AD mouse model, namely 5×FAD<sup>33</sup>, including a modified functional status and secretion of neuroinflammatory mediators. Apart from an

overlap with many previously described DAM genes (Extended Data Fig. 7a and Supplementary Data Table 2) and in light of the fact that the DAM signature typically is assigned to the cytoplasm of microglia and, thus, not entirely covered by our approach of applying snRNA-seq<sup>34</sup>, we also identified significantly differentially regulated genes (*Atg7*, *Ldlr*, *Rab7b*, *Pvt1*, *Mo1f*, *Neat1*, *Arhgap24* and *Tmem163*) in microglia of APPPS1 mice, which were not previously described as part of the DAM signature (Extended Data Fig. 7b and Supplementary Data Table 3).

Surprisingly, the inflammatory microglial gene signature of APPPS1 mice was largely unaffected by IL-12/IL-23 signaling, resulting in a similar differential gene regulation in microglia from both APPPS1 and APPPS1.*IL12b*<sup>-/-</sup> mice when compared to WT mice (Extended Data Fig. 7c–e). GO analysis showed that genes involved in ubiquitin protein ligase activity (*Mycbp2*, *Asb2*, *Rnf216*, *Rnf130* and *Znrf1*), thought to be linked to regulating neuroinflammation in AD<sup>35</sup>, were found to be slightly but significantly upregulated in WT versus APPPS1 mice but not significantly in APPPS1.*IL12b*<sup>-/-</sup> mice (Fig. 7c). Of note, we identified differentially expressed microglial genes known to be involved in phagocytosis (for example, *Picalm*) (Fig. 7d) or to be myelin related or amyloid related (Fig. 7e) when comparing microglia of APPPS1 mice to those of APPPS1.*IL12b*<sup>-/-</sup> mice. To validate the observed alterations in microglial genes affecting phagocytosis of A $\beta$  on a functional level, we assessed the activity of microglia in phagocytosing fluorescent beads in situ using organotypic brain slice cultures derived from WT and APPPS1 mice with or without functional IL-12 signaling (Fig. 7f). In accordance with the changes on the transcriptional level, the phagocytic activity of microglia from APPPS1 mice—both at the level of phagocytic cells and of the phagocytic index—was significantly reduced compared to WT microglia. Notably, microglia derived from APPPS1 mice lacking IL-12 signaling displayed a rescued phagocytic activity, where IL-12-deficient microglia were as efficient in eating up fluorescent beads as WT microglia (Fig. 7g,h), despite the fact that Clec7a (Dectin-1) intensities were not altered in Iba1<sup>+</sup> microglia adjacent to 4G8<sup>+</sup> A $\beta$  plaques in APPPS1 versus APPPS1.*IL12b*<sup>-/-</sup> mice (Fig. 7i,j).

In addition to protein-coding RNAs, non-coding RNAs are part of the microglial immune response<sup>36,37</sup>. Because the non-coding linear *Pvt1* and *circPvt1* as well as *Neat1* are capable of regulating the immune response<sup>38,39</sup>, we assessed their expression in APPPS1 mice with or without functional p40 signaling. *Pvt1* and *Neat1* were equally and indistinguishably upregulated in APPPS1 and APPPS1.*IL12b*<sup>-/-</sup> mice when compared to WT mice (Extended Data Fig. 7f–j), corroborating

our finding that the disease-associated coding and non-coding gene signature of microglia in A $\beta$ -bearing APPPS1 mice is independent of IL-12 in the hippocampus.

## Discussion

Our data unequivocally provide evidence that the IL-12/IL-23p40-mediated amelioration of AD pathology previously described by us<sup>7,8</sup> is mediated solely through IL-12 signaling, whereas IL-23 plays no role. Furthermore, our chosen approach of deleting IL-12 and IL-23 signaling in neuroectodermal cells of AD-like APPPS1 mice allows us to conclude that the crosstalk of AD-specific microglia-produced IL-12p40 (refs. 7,8) acts through neuronal and oligodendroglial IL-12 receptors, as oligodendrocytes and neurons harbor the respective transcripts, namely *IL12rb1* and *IL12rb2*. These transcripts were found to be equally present in AD-like and WT mice, with more cells expressing *IL12rb2*, whereas *IL12rb1* and *IL23r* expression—the latter of potential relevance for settings other than AD, where IL-23R signaling in the CNS may play a role—was restricted to fewer cells. Given that each of the two IL-12 receptor subunits can occur as dimers/oligomers differing only in their affinity to bind IL-12 (refs. 4–6), imbalanced subunit expression will not necessarily be rate-limiting in executing IL-12 actions. In contrast to the constitutive expression of IL-12 receptors, the expression of *IL12b* encoding for IL-12 ligand mainly by microglia was shown to occur AD-specifically in mice<sup>7</sup>. As the genetic repertoire for IL-12 signaling, namely *IL12RB1* and *IL12RB2* transcripts, is also present in neurons and oligodendrocytes in postmortem human primary motor cortex according to the Allen Brain Map, and because we found IL-12 receptor transcripts, but not those for IL-23 receptor, in postmortem hippocampi of human AD and control patients, the CNS IL-12/IL-23 signaling repertoire seems to be similar in mice and humans. In view of significantly increased IL-12p70 protein levels in AD brains compared to non-demented control cases, where higher Braak stages—indicative of a stronger cognitive decline—correlated with higher IL-12p70 protein expression, and given the profound response of human oligodendrocyte-like cells to IL-12 stimulation in vitro—in contrast to IL-23, which showed almost no effects—IL-12 appears to be an attractive and obvious druggable target in AD. Noteworthy, this contrasts with peripheral autoimmune diseases mediated through IL-12/IL-23 signaling, such as psoriasis or Crohn's disease, where IL-23 has been identified as the main driver<sup>40</sup>. In line with our data, Andreadou et al.<sup>41</sup> demonstrated that oligodendrocytes and neurons are the IL-12 receptor-bearing cell types in brain tissue

**Fig. 7 | Microglia in APPPS1 and APPPS1.*IL12b*<sup>-/-</sup> mice share gene signatures associated with enhanced microgliosis but exhibit distinct phagocytotic phenotypes. a**, Distinct homeostatic (yellow) and disease-associated (blue) microglia clusters were found in the combined snRNA-seq dataset with the disease-associated clusters present only in APPPS1 and APPPS1.*IL12b*<sup>-/-</sup> mice. **b**, Scatterplot comparing the gene expression in the disease-associated clusters versus the homeostatic clusters. **c**, GO analysis of differentially upregulated genes per indicated genotypes. The dot size illustrates gene ratio, and the color denotes *P* value. Violin plot showing log<sub>2</sub>FC of certain specific genes to the corresponding GO term. Fisher's exact test and the GO algorithm 'elim'. **d,e**, Volcano plots showing differentially expressed genes in microglia of APPPS1 mice compared to APPPS1.*IL12b*<sup>-/-</sup> mice (downregulated: blue; upregulated: red) known to be involved in phagocytosis of microglia (**d**) or to be myelin related or amyloid related (**e**). Adjusted *P* value by Benjamini–Hochberg. A cluster of selected AD risk genes involved in phagocytosis in ex vivo human microglia and human brain lysates<sup>68,69</sup> served as reference for assessing phagocytosis-related microglial transcriptome changes, which, upon conversion into their mouse orthologs, resulted in 27 genes comprising *Bin1*, *Ptk2b*, *Trem2*, *Zyx*, *Apbb3*, *Clu*, *Rin3*, *Cd33*, *Ms4a4a*, *Cr1l*, *Grn*, *Apoe*, *Picalm*, *Cd2ap*, *Plcg2*, *Sorl1*, *Fermt2*, *Ap4e1*, *Zkscan1*, *Abca7*, *Siglech*, *Trp53inp1*, *Abi3*, *Rabep1*, *Cass4*, *Ap4m1* and *Spp12a*. Myelin-related or amyloid-related transcriptome changes in microglia (right) were defined by referencing the gene list described by Depp et al.<sup>32</sup> (Supplementary Table 1, tab 6) depicting differentially expressed genes of DAM derived from 6-month-old mice with amyloid pathology and/or mutant


myelin, followed filtering by logFC > 0.25 and FDR < 0.01. Genes that were altered significantly are shown as filled circles (FDR < 0.05); open circles indicate differences that did not reach statistical significance. *IL12b* served as internal control. **f–h**, Phagocytic activity of microglia in adult acute brain slices of WT and APPPS1 mice with and without IL-12 signaling. Organotypic brain slices prepared from 90-day-old WT (*IL12b*<sup>+/+</sup>), *IL12b*<sup>-/-</sup>, APPPS1 and APPPS1.*IL12b*<sup>-/-</sup> mice were incubated with fluorescent microbeads to analyze phagocytic microglia. Representative views from 15- $\mu$ m confocal z-stacks showing uptake of fluorescent microbeads (in green) by microglia (labeled with Iba1, red) in brain slices of mice with the indicated genotypes (**f**). Percentage of phagocytic microglia with engulfed microbeads (*P* = 0.0104) (**g**) and phagocytic index (*P* = 0.0314) (**h**). For the calculation of the phagocytic index, phagocytic cells were grouped according to the number of ingested microbeads, with 1–3 microbeads = grade 1; 4–6 microbeads = grade 2; 7–10 microbeads = grade 3; and more than 10 microbeads = grade 4. Each grade (1–4) was multiplied with the respective percentage of phagocytic microglia to calculate the phagocytic index. Scale bar, 50  $\mu$ m. *n* = 4 mice per group (mean  $\pm$  s.e.m., one-way ANOVA with Dunnett's post hoc test with WT as control group). **i**, Representative immunohistochemical image of Clec7a, Iba1 and 4G8 staining in APPPS1.*IL12b*<sup>-/-</sup> mouse brain cortical tissue. Scale bar, 100  $\mu$ m. **j**, Clec7a staining intensity within plaque-associated Iba1<sup>+</sup> microglia in WT and APPPS1.*IL12b*<sup>-/-</sup> mice (*n* = 6). Mean  $\pm$  s.e.m., statistical analysis: two-tailed unpaired *t*-test with Bonferroni correction for each single bin, *P* = NS. NS, not significant.

of patients with multiple sclerosis (MS) and of experimental autoimmune encephalitis (EAE) mice, an inducible animal model of MS. However, in EAE, where pathology is mainly triggered by CNS-infiltrating peripheral immune cells, IL-12 has been shown to have a neuroprotective effect<sup>41</sup>, indicating that IL-12 appears to be yet another molecule with dual functions in inflammation versus degeneration of the CNS, as also shown for TREM2 (refs. 42,43) or granulocyte-macrophage colony-stimulating factor (GM-CSF)<sup>44,45</sup>. This can be explained by differences in the inflammatory context in the respective model, namely the amount, the cellular sources and duration of IL-12 action (rather short and high through monocyte-derived cells in EAE versus chronic and low in glial cells in AD-like mice).

### The oligodendroglial site of AD-related IL-12 signaling

How to interpret the herein-described IL-12-dependent reduction of mature oligodendrocytes in Aβ-overexpressing APPPS1 mice? Although

there is general agreement on the occurrence of white matter changes and myelin pathology in human patients with AD based on imaging and postmortem data<sup>46</sup>, animal studies using AD-like mice are inconclusive in this respect—possibly due to the fact that white and gray matter of the CNS differ in oligodendrocyte densities. While *in vivo* studies suggest that oligodendrocytes may be affected by the Aβ burden, resulting in a decrease in MBP<sup>47–49</sup>, other studies report that Aβ exposure to oligodendrocytes *in vitro* induces a more mature phenotype, as evidenced by an increase in oligodendrocyte branching and MBP production<sup>50</sup>. By comparing the overall oligodendrocyte numbers in AD-like mice and patients with AD, it has been suggested that the change in numbers reflects their dynamic alterations depending on the disease state<sup>51</sup>. Although previous studies reported an increase in Olig2<sup>+</sup> cells in the cortex of Aβ-overexpressing APPPS1 (ref. 51) and 5×FAD mice<sup>52</sup>, we found a substantial reduction of mature CCI<sup>+</sup>/Olig2<sup>+</sup> oligodendrocytes in the hippocampus, cortex and corpus callosum of amyloid-harboring and



neuroinflamed APPPS1 mice, which is entirely rescued to WT levels upon deleting IL-12. On a transcriptional level, we found no gross alterations in genes involved in regulating oligodendrocyte differentiation and maturation, whereas mature oligodendrocytes—presumably based on their IL-12/IL-23 signaling repertoire—were affected by the AD-specific amyloidogenic and inflammatory microenvironment. Similarly, IL-12 affected the myelination capacity of oligodendrocytes: immunohistochemical and ultrastructural analyses revealed a reduction in MBP and myelin sheath thickness in APPPS1 versus WT mice subsequently to the amyloid pathology at 250 days of age, which was restored in APPPS1.*Il12b*<sup>-/-</sup> mice. Along that line, treatment of co-cultures consisting of oligodendrocytes and neurons with IL-12p70 and IL-12p80 resulted in a decrease in myelination of neurofilament-positive axons as well as an overall decrease in cell numbers, which was accompanied by an increase in cleaved caspase-3, indicating IL-12-mediated cell death. Thus, our data corroborate previous findings on myelin pathology preceding AD pathology: loss of myelin integrity has been shown to be associated with the accumulation of A $\beta$  in imaging studies<sup>53</sup>, in post-mortem human brain tissue<sup>54</sup> and experimentally in several mouse models of AD, namely 3 $\times$ Tg-AD, Tg2576, APPPS1, 5 $\times$ FAD and APP<sup>NLGF</sup>, where myelin abnormalities impair clearance of A $\beta$ <sup>32,55,56</sup>. Myelin perturbation was shown to increase the risk of developing or exacerbating AD—for example, by altering components of the A $\beta$ -generating machinery, including the amyloid precursor protein (APP) and the APP-cleaving enzyme BACE1 (refs. 32,57), or by distracting microglia-mediated breakdown of A $\beta$  due to redeployment of these cells to sites of myelin damage<sup>32</sup>. Because IL-12 signaling in oligodendrocytes acts through STAT4/pSTAT4 (ref. 58), which can lead to an increase in interferon- $\gamma$  known to generate myelin and oligodendrocyte loss in aged mice<sup>59</sup>, the co-occurrence and interplay of neuroinflammation and myelin defects may exacerbate AD pathology by creating a ‘vicious circle’.

### The neuronal site of AD-related IL-12 signaling

In addition to substantially affecting oligodendrocytes, IL-12/IL-23 signaling also altered the gene signatures of subicular neurons of the hippocampus—a brain region of high relevance for cognitive functions. Atrophy in the subiculum is thought to be the earliest sign of neuronal degeneration in AD<sup>11</sup> and is connected to memory loss<sup>60</sup>. The subiculum’s role in controlling hippocampal output is substantially influenced by its inherent GABAergic activity: local GABAergic signaling limits the spread of incoming excitation and alters the activity patterns of the subiculum’s principal cells (PCs). Notably, local inhibition impacts intrinsically bursting (IB) neurons, which are thought to be key in the output activity of the subiculum, therefore shaping memory<sup>60</sup>. Studies have reported that neuronal cell death and ultimately cognitive decline in AD can be attributed to hyperexcitable microcircuits due to a loss of GABAergic interneurons. Quantification of PV<sup>+</sup> interneurons in the hippocampus revealed a hitherto unrecognized reduction of GABAergic interneurons in APPPS1 compared to WT mice, which was restored in IL-12-deficient littermates. These data provide a morphological substrate for the impaired cognitive performance in these mice<sup>7</sup> and corroborate the IL-12-mediated impact on the neuronal phenotype in these mice.

Although subicular neurons were decreased in APPPS1 mice irrespective of *Il12b*, their transcriptional signature was altered, depending on the expression of IL-12, for genes involved in memory and synaptic plasticity, such as *ErbB4* and *Rarb*, as well as genes regulating dendrite development, such as *Nrp1* and *Nrp2* encoding Neuropilin-1 and Neuropilin-2. As KEGG signaling pathway analysis closely relates NRP1 regulation to the AKT pathway that can get activated by IL-12, and as NRP1 depletion was shown to attenuate phosphorylation of AKT, GSK3 $\beta$  and mTOR proteins<sup>61</sup>, IL-12 may well directly impact NRP1-mediated dendrite development. Another IL-12-mediated mechanism affecting neuronal homeostasis is *Nrg*–*ErbB* signaling, which links oligodendrocyte and neuronal interaction and mediates a plethora of cellular

functions in both cell types<sup>62</sup>, including *Nrg1*–*ErbB*-driven regulation of axonal pathfinding, synaptic behavior and neuronal migration<sup>63,64</sup>.

### Mechanism of action

From a mechanistic viewpoint, the reduction of A $\beta$  burden upon IL-12 deficiency appears to occur by an increase in A $\beta$  clearance, as the APP transgene and genes involved in its processing were not substantially altered in neurons of APPPS1 versus APPPS1.*Il12b*<sup>-/-</sup> mice, and APP protein expression and its respective processing machinery, including the degradation enzymes, were shown to be unaltered in APPPS1 mice deficient in IL-12 signaling<sup>7</sup>. The fact that microglia from APPPS1 mice lacking IL-12 signaling appear to be less distracted by myelin debris may well explain why they have a greater capacity to successfully clear A $\beta$  than microglia of APPPS1 mice with functional IL-12 signaling. This assumption is based not only on myelin-related and amyloid-related alterations in the transcriptome of microglia and by their increase in expression of phagocytosis-related genes, such as *Picalm*, but also on a functional level, where microglia within organotypic brain slices from APPPS1 mice lacking IL-12 signaling displayed a phagocytic activity alike WT mice, whereas APPPS1 control microglia presented with a substantially reduced capacity to phagocytose. At the same time, the lack of IL-12/IL-23 signaling in AD-like APPPS1 mice did not change the inflammatory state of IL-12/IL-23(p40)-producing microglia substantially, including parts of the DAM APPPS1-specific signatures. One possible explanation is that capturing nuclear RNA by snRNA-seq may exclude cytoplasmic RNA, which is part of the presently defined full DAM signature spectrum<sup>33</sup>. Apart from observing an overlap with the previously described DAM genes, such as *Axl*, *Clec7* and *Cd9*, we also discovered a distinct set of microglia-specific disease-associated genes. As inflammatory transcriptional DAM signatures are thought to cause many changes in microglia, this notable lack of more obvious changes of IL-12/IL-23(p40)-producing microglia apart from those related to their phagocytic capacity may be because paracrine signaling of microglia affects primarily other IL-12/IL-23 recipient-prone CNS-intrinsic cells. This notion is supported by the fact that microglia (including those expressing the activation marker *Clec7a*) from APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> mice are similarly distributed around amyloid plaques, suggesting that the described changes in APPPS1.*Il12b*<sup>-/-</sup> mice are mediated mainly through the above-described IL-12 receptor-triggered oligodendrocyte and/or neuronal phenotype(s). Further evidence for this interpretation comes from the fact that aging-associated myelin dysfunction has recently been shown to result in a stark increase of amyloid deposition around swollen myelin in AD-like mice preferentially in the alveus of the hippocampus but not in the fimbria<sup>32</sup>. The herein-reported lack of changes in microglia of APPPS1.*Il12b*<sup>-/-</sup> versus APPPS1 mice in light of the pronounced loss of mature oligodendrocytes and impaired myelin integrity may, thus, indicate that the reduction of amyloid upon IL-12 deficiency is rather a result of the inhibition of the AD-specific IL-12-dependent disintegration of myelin (driving enhanced A $\beta$  deposition) than a consequence of an increase in microglial phagocytosis.

### Limitation of the study

Given the pronounced oligodendrocyte phenotype in APPPS1 mice, our study cannot discriminate whether the described neuronal gene alterations as well as the reduction in PV<sup>+</sup> interneurons are a secondary, indirect effect resulting in oligodendrocyte/myelin alterations or whether the observed neuronal changes are directly IL-12 mediated, which may induce subsequent oligodendrocyte/myelin pathology. The close functional relationship between neurons and oligodendrocytes, for example due to the trophic support of neurons by oligodendrocytes, makes both scenarios, or a mixture thereof, possible. Dissecting the precise sequence of IL-12-mediated alterations will, thus, be a topic of future investigations.

In conclusion, our data are not only instrumental in dissecting the mechanism of IL-12/IL-23-specific immunomodulation of AD by

identifying its cellular targets, namely oligodendrocytes and neurons, and by linking myelin changes with the capacity of microglia to phagocytose A $\beta$ ; they also highlight the potential of an IL-12/IL-23 targeted immunotherapy in AD. The fact that IL-12, but not IL-23, is the pathogenetically relevant pathway in AD-related IL-12/IL-23 signaling—of note and in contrast to other IL-12/IL-23-mediated (non-neurological) disorders, such as Crohn's disease, rheumatoid arthritis or psoriasis, where IL-23 is the main player—may also encourage the use of exclusive IL-12 inhibition in tackling AD.

## Methods

All animal experiments were conducted in accordance with animal welfare acts and were approved by the regional office for health and social service in Berlin (LaGeSo; license O 298/17, T 0276/07 and T-CH0022/23). Human tissue sampling, processing and subsequent analyses were done on the basis of ethical approval number EA1/144/13 granted by the Ethics Board of the Charité – Universitätsmedizin Berlin, Germany. Human postmortem CNS tissue was collected and snap frozen from patients who had given written informed consent before death. Postmortem brain tissue from the University of Florida Human Brain and Tissue Bank (UF HBTB) was collected with approval from the University of Florida Institutional Review Board (IRB201600067). All patients or their next of kin gave written informed consent for the brain donation and use of tissue specimens for research.

## Mice

Heterozygous APPPS1<sup>+/-</sup> mice (previously described by Radde et al.<sup>65</sup>, co-expressing KM670/671NL-mutated APP and L166P-mutated presenilin 1 (PS1) under the control of a neuron-specific Thy1 promoter element, termed APPPS1 mice) were crossed to *Il12b*<sup>-/-</sup> (ref. 66) mice and compared to WT littermate controls. Mice were bred on a C57BL/6J background. *Il12rb2*<sup>fl/fl</sup> mice, generated and characterized previously<sup>67,68</sup>, were crossed to APPPS1 and heterozygous Nestin<sup>Cre</sup> mice<sup>69</sup> (The Jackson Laboratory, stock no. 0037719), resulting in the APPPS1<sup>+/-</sup>.Nestin<sup>Cre</sup>.*Il12rb2*<sup>fl/fl</sup> strain. The animals used for the experiments represented in Fig. 1a,b are littermates. The genotype annotated as APPPS1 represents APPPS1<sup>+/-</sup>.Nestin<sup>WT</sup>.*Il12rb*<sup>WT/WT</sup> with the *Il12rb2* gene still intact due to the lack of Cre recombinase expression and the lack of the LoxP site, and the genotype annotated as APPPS1.Nestin<sup>Cre</sup>.*Il12rb2*<sup>fl/fl</sup> represents APPPS1<sup>+/-</sup>.Nestin<sup>Cre</sup>.*Il12rb2*<sup>fl/fl</sup> animals with exon 7 excision of *Il12rb* in Nestin<sup>+</sup>, neuroectodermal cells (neurons, oligodendrocyte lineage cells and astrocytes). The APPPS1<sup>+/-</sup>.Nestin<sup>Cre</sup>.*Il23r*<sup>fl/fl</sup> strain was generated by crossing the heterozygous APPPS1<sup>+/-</sup> mouse model to the homozygous *Il23r*<sup>fl/fl</sup> line<sup>70</sup>, where exon 4 of the *Il23r* gene is flanked by two LoxP sites, as well as the Nestin<sup>Cre</sup> reporter mice. The animals used for the experiments represented in Fig. 1a,c are littermates. The genotype annotated as APPPS1 represents APPPS1<sup>+/-</sup>.Nestin<sup>WT</sup>.*Il23r*<sup>fl/fl</sup> mice with the *Il23r* gene still intact due to the absence of Cre recombinase expression, and APPPS1.Nestin<sup>Cre</sup>.*Il23r*<sup>fl/fl</sup> represents APPPS1<sup>+/-</sup>.Nestin<sup>Cre</sup>.*Il23r*<sup>fl/fl</sup> mice with exon 4 excision of *Il23r* in Nestin<sup>+</sup> cells.

Animals were kept in individually ventilated cages with a 12-h light/dark cycle with food and water ad libitum.

## snRNA-seq

Mouse hippocampi were harvested from male WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> mice at the age of 250 days, immediately snap frozen in liquid nitrogen and stored at -80 °C until further processing. Nuclei were isolated from a single hippocampus in 2 ml of pre-chilled EZ PREP lysis buffer (Sigma-Aldrich, NUC-101) using a glass Dounce tissue grinder (Sigma-Aldrich, D8938) (25 strokes with pestle A and 25 strokes with pestle B), followed by incubation for 5 min on ice with an additional 2 ml of EZ PREP buffer. During incubation, 1  $\mu$ M DAPI was added to the homogenate, which was then filtered through a 30  $\mu$ M FACS tube filter. A BD FACSAria III flow cytometer with a 70- $\mu$ m nozzle

configuration was used to sort the nuclei based on the fluorescent DAPI signal at 4 °C. As CNS nuclei vary strongly in size, no doublet discrimination was performed based on forward scatter (FSC) or side scatter (SSC) to avoid bias. Nuclei were counted based on bright-field image and DAPI fluorescence using a Neubauer counting chamber and a Keyence BZX-710 microscope. Isolated nuclei were immediately used for droplet-based 3'-end single-cell RNA-seq using the Chromium Next GEM Single Cell 3' GEM, Library & Gel Bead Kit, version 3.1, following the manufacturer's instructions (10x Genomics, PN-1000121). The libraries were multiplexed, and three samples per lane were sequenced on an Illumina HiSeq 4000 sequencer. Demultiplexing, barcode processing, read alignment and gene expression quantification were carried out using Cell Ranger software (version 3.1.0; 10x Genomics). First, Cell Ranger mkfastq demultiplexed the sequencing by sample index. The quality of the data was checked using FastQC (version 0.11.5), and all samples showed high-quality RNA-seq data with good median per-base quality ( $\geq 28$ ) across most of the read length. Cell Ranger count used STAR software with default parameters to align sequenced reads to the reference genome (GRCm38, Ensembl GTF, version 98). As nuclei have a high amount of pre-mRNA, we generated a custom pre-mRNA reference based with the instructions provided on the 10x Genomics website; we also included intronic reads in the final gene expression counts. Finally, the output files for all nine samples were aggregated into one gene-cell matrix using Cell Ranger 'aggr' without read depth normalization.

## snRNA-seq data analysis

Data were analyzed in R (version 3.6.0) using Seurat (version 3.1.2)<sup>71</sup>. In all downstream analyses, the filtered feature-barcode matrix was used rather than the raw feature-barcode matrix. For the initial quality control, we excluded genes expressed in fewer than three nuclei and nuclei expressing fewer than 200 genes or fewer than 500 or more than 30,000 UMIs and nuclei with more than 5% mitochondrial reads. This resulted in a dataset of 84,002 cells and 31,790 quantified genes across nine samples. We then normalized UMI counts using the 'Log-Normalize' method and by applying a scale factor of 10,000. We found variable genes using 'FindVariableFeatures' with the selection method 'vst'. Data regression was performed using the ScaleData function with nUMI, percent mitochondrial counts and sample origin as confounding factors. Dimensionality reduction was performed using principal component analysis (PCA), and we selected 40 principal components based on elbow plot. The 'FindNeighbors' function, which implements shared nearest neighbor (SNN) modularity optimization-based clustering algorithm, was applied and identified clusters with a resolution of 0.8 by the 'FindClusters' function, resulting in 45 initial clusters. A further dimensionality reduction step was carried out, using the UMAP algorithm to visualize the data. The UMAP parameters were as follows: n.neighbors = 20, min.dist = 0.35, n.epochs = 500, spread = 2. As UMAP overlay by individual sample shows minimal batch effects, we did not consider any batch correction method. For assigning clusters to cell types, we used the 'FindAllMarkers' function with default parameters, identifying negative and positive markers for that cluster. Scrublet (version 0.21)<sup>72</sup> with an expected\_doublet\_rate = 0.06 was applied, resulting in detection of 5.2% of doublets. We defined doublet clusters as containing more than 50% of doublets and removed these for downstream analysis. We noticed that these clusters were projected in the middle of other cell types in UMAP and were validated as expressing marker genes from two different cell types. We eventually removed eight clusters, which reduced our dataset to 82,298 nuclei. Cell type variability was measured using an entropy-based approach<sup>73</sup>. We first grouped by replicate and genotype. The local neighborhood was defined by taking the 30 nearest neighbors using kNN-Graph and the relative entropy. We applied Kullback-Leibler divergence to measure how cells are distributed among samples. Controls were randomly shuffled and showed that differences detected in gene signature were of biological relevance

and not driven by technical artifacts. One-way ANOVA was used to test whether cellular proportions differed by genotype. Homogeneity of variance and normality of data distribution were assessed by using Bartlett and Shapiro–Wilk tests, respectively, with the R package ‘stats’ (version 3.6.0). A  $P$  value of less than 0.05 was considered statistically significant. To identify differentially regulated genes among genotypes, we performed empirical Bayes quasi-likelihood  $F$ -tests (QLF) including the cellular detection rate (the fraction of detected genes per cell) using EdgeR (version 3.28.1)<sup>74,75</sup>. A  $\log_2$  fold change (FC) greater than 0.25 and a false discovery rate (FDR) less than 0.01 were considered significant. Among differentially expressed genes, we removed the *Ttr* gene as its expression was highly dependent on the presence of a choroid plexus cluster in a given sample, suggesting a dissection bias at the stage of hippocampus isolation. GO term enrichment of each cluster was performed with topGO (version 2.36.0)<sup>76</sup>. In GO analysis, genes showing average  $\log_2$ FC > 0.25 and adjusted  $P < 0.01$  were considered significant, and all expressed genes were used as background. We used the ‘elim’ algorithm instead of the classic method to be more conservative and excluded broad GO terms with more than 1,000 listed reference genes. We performed trajectory inference with SCORPIUS (version 1.0.7)<sup>77</sup> for oligodendrocyte populations, including OPCs. To infer developmental trajectory, we used highly variable and all expressed transcriptional factor genes and reduced dimension using distance metric as Spearman with 3 number of dimensions. To infer gene expression along the pseudotime, we first downloaded a list of genes from Mouse Genome Informatics (<http://www.informatics.jax.org>) displaying negative regulation of oligodendrocyte differentiation (GO:0048715) and positive regulation of oligodendrocyte differentiation (GO:0048714), which was smoothed over pseudotime using a generalized additive model using ‘mgcv’ (version 1.8-28). We used CellPhoneDB (version 2.1.1)<sup>27</sup> to assess cellular crosstalk between different cell types. To identify putative cell–cell interactions via multi-subunit ligand–receptor complex pairs, label permutation was performed. First, we converted mouse gene symbols to human gene symbols using biomaRt (version 2.42.1)<sup>78</sup> and removed duplicated gene symbols from digital gene expression matrix. We then calculated normalized data with scale factor 10,000. Finally, we conducted statistical analyses by randomly permuting the cluster labels of each cell 10,000 times.

A list of DAM genes was downloaded from the work by Keren-Shaul et al.<sup>33</sup>. This DAM signature was collected from single-cell sorting and downstream single-cell RNA-seq of microglia from the AD mouse model 5×FAD. We computed the  $\log_2$ FCs of the Microglia 3 (Disease-associated cluster) to Microglia 1 (Homeostatic cluster) ratio for each gene<sup>33</sup>, resulting in 461 DAM genes. To identify DAM APPPS1-related signature genes from our dataset, we compared the differential expression of cluster 8 (disease state) and cluster 3 (homeostatic state), where only  $\log_2$ FC > 0.25 and FDR < 0.01 were considered, ultimately resulting in 488 genes. Ninety-six genes intersected between our study and the already published study<sup>33</sup>. Of those, 365 genes were specific for the published DAM signature, whereas 392 genes were specific to our APPPS1-related dataset.

To visualize read coverage of snRNA-seq data in a genome browser, Sambamba (version 0.6.8)<sup>79</sup> was used to sort BAM file produced from 10x Cell Ranger count. We extracted only primary alignment reads from sorted BAM file and created a bedgraph file using bedtools (version 2.27.1)<sup>80</sup> with normalized using read depth and split file by strand specific. Finally, we created a BigWig file using bedGraphToBigWig (version 4)<sup>81</sup>, and the resulting genomic signal tracks were visualized in the UCSC Genome Browser. The results of genome tracks are located in public hubs at the MDC Genome web browser (<https://genome.mdc-berlin.de/>).

To validate our results derived from analyzing human postmortem brain tissue (Fig. 3f), we downloaded gene matrix and meta data of primary motor cortex from <https://portal.brain-map.org/> (ref. 82). Like previous analyses using Seurat (version 4), we filtered genes expressed

in fewer than three nuclei. We then normalized UMI counts and found variable genes using ‘vst’ and kept 2,000 highly variable genes (HVGs). We scaled data to perform PCA and selected 40 principal components for downstream analyses, FindNeighbor, FindCluster and RunUMAP. Cell types were assigned by information from meta data.

### Bulk RNA-seq and analysis

Total RNA was isolated from freshly frozen hippocampi from 250-day-old animals using a NucleoSpin miRNA and RNA purification kit (Macherey Nagel, 740971.50). The tissue was homogenized using a Pellet Mixer (VWR, 431-0100) in 0.35 ml of Buffer ML provided in the RNA purification kit and subsequently passing the homogenate through a 23-gauge needle (B. Braun, 465 7667) until no clumps remained. RNA was isolated according to the manufacturer’s protocol and eluted in 20  $\mu$ l of RNase-free water. Library construction and bulk mRNA-seq were performed by Novogen (non-stranded cDNA libraries; 150-bp paired-end run with a depth of 40 million reads per library). Bulk transcriptomes were aligned using STAR (version 2.7.1a)<sup>83</sup> with mm10 reference and quantified using featureCounts (version 1.6.0). Differential expression genes between samples were determined as adjusted  $P$  value less than 0.05 and FC higher than 1 or lower than –1 using DESeq2 (version 1.24.0)<sup>84</sup>, using default option without the lfcShrink function. To analyze pairwise correlations between bulk transcriptomes and snRNA-seq data, bulk transcriptomes were converted to transcripts per million (TPM) by dividing each count of each gene by its length and multiplying by 1 million. Each gene length was calculated from GTFtools (version 0.6.9)<sup>85</sup> by median length of its isoforms. snRNA-seq expression counts were summed by each sample and converted to counts per million (CPM). The scale of all figures is  $\log_2$  (CPM/TPM + 1). To validate the findings provided by bulk transcriptomics regarding the ratio of various CNS cell types, we performed weighted non-negative least squares for cell type proportion estimation using Multi-subject Single Cell deconvolution (MuSiC) (version 0.1.1)<sup>16</sup>. We ran the package with default settings with HVGs from snRNA-seq data.

### Multiplex smFISH

Frozen brain tissue was placed in a tissue mold (Sakura, SA62534-15) and submerged in Tissue-Tek freezing medium (Sakura, 4583). Then, 10- $\mu$ m-thick tissue sections were cut using a cryostat (Thermo Fisher Scientific, HM 560), placed on SuperFrost Plus slides (R. Langenbrink, 500621) and dried for 1 h at –20 °C. Tissue processing for RNAscope multiplex staining (Advanced Cell Diagnostics) was done following the manufacturer’s protocol for fresh-frozen sections. In brief, tissue was fixed in freshly prepared 4% paraformaldehyde (PFA) (pH 7.4) for 30 min at 4 °C, followed by alcohol dehydration. Tissue was exposed at room temperature to the given concentration of H<sub>2</sub>O<sub>2</sub> for 10 min and to Protease IV (Bio-Techne, 322340) for 30 min and then incubated for 2 h with target probes at 40 °C in a HybEZ Hybridization System (Bio-Techne, 321711). The following target probes were used: Mm-Il12rb1 (Bio-Techne, 488761), Mm-Il12rb2 (Bio-Techne, 451301), Mm-Il23r (Bio-Techne, 403751), Mm-Aldh1l1-C2 (Bio-Techne, 405891-C2), Mm-Slc1a3-C2 (Bio-Techne, 430781-C2), Mm-Gfap-C2 (Bio-Techne, 313211-C2), Mm-Sox10-C2 (Bio-Techne, 435931-C2), Mm-Tmem119-C3 (Bio-Techne, 472901-C3), Mm-Sall1-C3 (Bio-Techne, 469661-C3), Mm-Rbfox3-C3 (Bio-Techne, 313311-C3) and Mm-Map2-C3 (Bio-Techne, 431151-C3). Signal amplification was achieved using an RNAscope Multiplex Fluorescent Kit, version 2 (Bio-Techne, 323110), closely following the manufacturer’s protocol. Probes were labeled with Opal 520 (1:500; C2 probe, FP1487001KT; PerkinElmer), Opal 570 (1:500; C1 probe, FP1488001KT; PerkinElmer) and Opal 690 (1:500; C3 probe, FP1497001KT; PerkinElmer), and three-dimensional image stacks (1  $\mu$ m step size,  $\times$ 40 objective) of stained sections were taken on a Leica TCS SP5 confocal laser scanning microscope using an HCX PL APO lambda blue  $\times$ 63 oil UV objective controlled by LAS AF scan software (Leica Microsystems).

### Electron microscopy imaging

Tissue processing and electron microscopy imaging were performed as described previously<sup>86</sup>. In brief, animals were perfused with 10 ml of HBSS (Gibco, 24020117) followed by perfusion with 30 ml of Karlsson Schultz buffer, pH 7.4 (4% formaldehyde, 2.5% glutaraldehyde EM grade, 0.5% NaCl in phosphate buffer, pH 7.4)<sup>87</sup>. After perfusion, brains were further fixed in Karlsson Schultz buffer for an additional 24 h at 4 °C, followed by storage in 1% PFA in phosphate buffer, pH 7.4, until further processing. Then, 200- $\mu$ m coronal sections of brains were cut using a Leica VT1200S vibratome. The caudal part of the corpus callosum, including the alveus as well as the fimbria, was punched out of the section using a 1-mm Harris Uni-core Punch and embedded in Epon (Serva) after post-fixation with 2% OsO<sub>4</sub> (Science Services) and dehydration using acetone. Epon-embedded samples were cut using a microtome (Leica, UC7). Semi-thin sections were collected to verify the region of interest (ROI) using a light microscope. Ultra-thin 50-nm sections were placed on hexagonal copper grids (Gilder) coated with 'Formvar' (Plano) and stained with Uranylless (Science Services). Ultra-thin sections were analyzed using a LEO912 electron microscope (Zeiss), and pictures were obtained using a wide-angle dual-speed 2K-CCD camera (TRS) at  $\times 5,000$  magnification. To quantitatively compare the axons between the groups, the electron microscopy images were analyzed using ImageJ. To avoid bias, all image analyses were done blinded, and a grid was put onto each image, and those axons that touched the angles were measured, in total 20 axons per image. The axon areas were measured using the free-hand tool to outline the outer layer of the axoplasm membrane. To account for myelin thickness, the inner tongue of the myelin sheath was measured as well as the outer layer, which was also used for axon diameter calculation. The axon and fiber diameters were calculated from the measured axon area using the formula  $2 \times \sqrt{A/\pi}$ . Axon sheath thickness was then calculated by subtracting the axon diameter from the fiber diameter. The g-ratio was calculated by dividing the axon diameter by the fiber diameter. The data were tested for normality using the Shapiro–Wilk test. Differences in g-ratios of the observed groups were compared and tested with the Kruskal–Wallis test for non-parametric data in multiple groups. The results were adjusted using the Bonferroni correction for multiple testing.

### Immunohistochemical stainings, quantitative assessments and microglial phagocytosis assay

Animals were perfused with PBS, and hemispheres were fixed for 24 h in 4% PFA at 4 °C. Brains were further processed by incubating them in 10%, 20% and, finally, 30% sucrose in PBS over the course of 3 days. Free-floating brain sections were cut at 30–40- $\mu$ m thickness using a cryostat (Thermo Fisher Scientific, NX70 957030L) and stored in cryoprotectant (0.65 g of NaH<sub>2</sub>PO<sub>4</sub>  $\times$  H<sub>2</sub>O, 2.8 g of Na<sub>2</sub>HPO<sub>4</sub> in 250 ml of ddH<sub>2</sub>O, pH 7.4, with 150 ml of ethylene glycol and 125 ml of glycerine) at 4 °C until further use. Sections were stained by first incubating them in 0.3% Triton-X in PBS with 10% normal goat serum for 1 h. The primary antibodies used for detecting oligodendrocytes were Olig2 (rabbit, 1:750, AB9610; Millipore), CCI (mouse, 1:200, OP80-100UG; Merck) and MBP (rat, 1:200, MCA409S; Bio-Rad); PV (rabbit, 1:200, MAB1572; Millipore) for depicting interneurons; Clec7a (rat, 1:150, mapg-mdect; InvivoGen) and Iba1 (rabbit, 1:500, 019-19741; Wako) for identifying microglia; and 4G8 (mouse, 1:1,000, SIG39320; Covance) for visualizing A $\beta$  plaques, and all were incubated at 4 °C overnight. The secondary antibodies Alexa Fluor 568 goat anti-rabbit (A11011), Alexa Fluor 488 goat anti-mouse IgG (A11001), Alexa Fluor 488 goat anti-mouse IgG2b (A21141), Alexa Fluor 647 goat anti-rabbit (A21244), all Invitrogen; Cy3 donkey anti-rat IgG (Jackson ImmunoResearch, 712-165-153); and Alexa Fluor 488 goat anti-rat (112-545-003, 1:300; Dianova) were added for 2 h at room temperature. Nuclei were counterstained using 500 nM DAPI for 1 min.

For assessment of oligodendrocytes, 3–6 brain sections were stained and imaged with an inverted microscope (Leica, DMI 6000)

at  $\times 40$  magnification. Images were stitched together automatically using LAS X 3.3 Stage Experiment TileScan software (Leica). Based on the DAPI-stained image, the hippocampus was set as the ROI. Based on a fixed threshold for all images, ImageJ was applied to quantify all DAPI as well as Olig2<sup>+</sup> nuclei using the 'Analyze Particle' function. The total count of Olig2<sup>+</sup> nuclei was normalized to the total counts of DAPI<sup>+</sup> nuclei. For technical reasons, CCI<sup>+</sup> cells were counted manually with the Cell Counter tool in ImageJ and normalized to Olig2<sup>+</sup> cells. Similarly, cell bodies of PV<sup>+</sup> interneurons were counted using the Cell Counter tool in ImageJ within a tissue area of  $2 \times 10^4 \mu\text{m}^2$  in the CA1 and within a tissue area of  $3 \times 10^4 \mu\text{m}^2$  in the cortex. Images were taken with an inverted Nikon spinning disk confocal microscope at a magnification of  $\times 10$ . Three distinct but equally located ROIs were analyzed per tissue section. The mean gray value of MBP in the corpus callosum was calculated via binarization based on a threshold within the defined ROI and normalized to DAPI mean gray value of the same image. The MBP-covered area in the cortex was measured with the 'Analyze Particles' tool in ImageJ. Methods were adapted from published data<sup>88</sup>.

Preparation of acute cortical brain slices from 90-day-old *Il12b<sup>+/+</sup>*, *Il12b<sup>-/-</sup>*, *APPPS1.Il12b<sup>+/+</sup>* and *APPPS1.Il12b<sup>-/-</sup>* mice followed previously described protocols<sup>89</sup>: mice were decapitated, and brains were removed and washed in artificial CSF (aCSF), containing 134 mM NaCl, 2.5 mM KCl, 1.3 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 1.25 mM K<sub>2</sub>HPO<sub>4</sub>, 26 mM NaHCO<sub>3</sub> and 10 nM D-glucose, pH 7.4, which was saturated with carbogen (95% O<sub>2</sub>, 5% CO<sub>2</sub>). Coronal cortical slices at 130- $\mu$ m thickness were prepared at 4 °C using a vibratome and were then kept in aCSF at room temperature for 2 h until phagocytosis experiment. The microglial phagocytosis assay in acute brain slices was done as described previously<sup>89</sup>. In brief, yellowgreen fluorescent Fluoresbrite carboxylated microspheres (2  $\mu$ m diameter; Polysciences Europe) were coated with FCS by shaking at 100g for 30 min at room temperature. Microspheres were centrifuged at 1,000g for 5 min and then washed twice in HBSS and applied on acute brain slices at  $8.4 \times 10^6$  microspheres per well. Slices were incubated for 1 h at 37 °C. Afterwards, they were washed twice with 1 $\times$  PBS on an orbital shaker for 15 min and then fixed with 4% PFA for 1 h at room temperature. To prepare the tissue for analyzing microglia phagocytosis, fixed slices were permeabilized in 2% TX in PBS for 4 h at room temperature on a shaker, and then unspecific binding sites were blocked by incubation in 10% NGS/2% TX/2% BSA for 2 h at room temperature. Primary antibody Iba1 was diluted at 1:300 in 5% NGS/0.3% TX in PBS and incubated with slices overnight at 4 °C. The next day, slices were washed three times in 1 $\times$  PBS, and secondary antibody (goat anti-rabbit Alexa Fluor 568, 1:300, in PBS/5% NGS/0.3% TX) was incubated for 2 h at room temperature. After washing slices three times with 1 $\times$  PBS, they were counterstained with Draq5 (1:1,000 in PBS; eBioscience) for 10 min and then mounted with Microscopy Aquatex (Merck). For assessing microglial phagocytosis, 15- $\mu$ m-thick z-stacks with a step size of 1  $\mu$ m, beginning from the top of the slice, where the microspheres are located, were taken at  $\times 40$  magnification using a confocal laser scanning microscope (Zeiss, LSM 510 META). Four to five z-stacks per slice were analyzed by determining the percentage of phagocytic microglia per field of view using the ImageJ Cell Counter plugin. Furthermore, phagocytic cells were grouped according to the number of microspheres they had taken up, to determine the phagocytosis grade of microglia, with 1–3 microspheres = grade 1; 4–6 = grade 2; 7–10 = grade 3; and more than 10 = grade 4.

To assess the expression of Clec7a by microglia in tissue sections of brains of mice, image stacks were taken with an inverted Nikon spinning disk confocal microscope at a magnification of  $\times 20$ . Three distinct but equally located ROIs were analyzed per section with 12 sections per animal. Clec7a expression levels of plaque-associated microglia (Fig. 7h) were quantified from maximum projections of the confocal stacks. The quantification was performed in an automated manner using custom-written ImageJ macros (segmentation)<sup>90</sup> and Python scripts (statistics and distance measurements), which

can be found on GitHub<sup>91</sup>. The data displayed in the histogram were binned image-wise, normalized (divided by their own integral) and then pooled by calculating the median from all images per animal and plotting the mean and s.e.m. of all animals from one group. DAPI signal was de-noised (frequency filter in Fourier space for structures above 2.6  $\mu\text{m}$ ) and blurred (Gaussian blur,  $\sigma = 520 \text{ nm}$ ) before using StarDist<sup>92</sup> ('versatile fluorescent nuclei model') to segment nuclei. Watershed segmentation was then applied to the Euclidean distance map of the binary images to separate merged nuclei. Plaques were segmented from the de-noised 4G8 channel (frequency filter in Fourier space for structures above 26  $\mu\text{m}$ ), followed by 'rolling ball' background subtraction (radius = 52  $\mu\text{m}$ ) and Otsu binarization. Only objects above 130  $\mu\text{m}^2$  were regarded as plaques. The mean intensities within segmented nuclear regions (s. above) were used as a measure for Iba1 and Clec7a expression levels. Cells were classified as Iba1 positive/negative by auto-thresholding (Otsu's method on all cell-specific expression levels within one image). Only Iba1<sup>+</sup> cells within 30  $\mu\text{m}$  around plaques were used for analysis.

### Mouse brain tissue protein extraction and quantification

Brain tissue used for protein extraction was harvested from PBS-perfused animals. Snap-frozen proteins were extracted based on their solubility as previously described<sup>93</sup>: thawed hemispheres with removed cerebellum were homogenized successively in TBS buffer pH 7.6 (20 mM Tris, 137 mM NaCl), Triton-X buffer (TBS buffer supplemented with 1% Triton X-100) and SDS buffer (2% SDS in ddH<sub>2</sub>O). All buffers were kept on ice and supplemented with cOmplete Mini Protease Inhibitor Cocktail Tablets (Roche, 11836153001). Initial homogenization was performed mechanically using a tissue homogenizer (VWR, 431-0100), followed by passing the homogenate through a 2-ml syringe with a G25 cannula (BD Microlance, 03086976). TBS and Triton-X brain extracts were incubated for 30 min on ice, and SDS homogenate was incubated at room temperature and vortexed every 5 min. After incubation, the homogenate was centrifuged at 100,000g for 45 min at 4 °C. The supernatant was collected, snap frozen in liquid nitrogen and stored at 80 °C until further use. The residual pellet was re-suspended in succeeding buffers. Total protein concentration was quantified via QuantiPro BCA Protein Assay Kit (Pierce) according to the manufacturer's protocol using an Infinite M200 photometer (Tecan). White and gray matter were isolated from the corpus callosum and cortex of mouse brains and homogenized in PBS, and the protein concentration was adjusted by BCA assay to 1 mg ml<sup>-1</sup> protein before its use for mass spectrometry. To assess A $\beta$  levels, the 96-well MultiSpot Human 6E10 A $\beta$  Triplex Assay Kit (Meso Scale Diagnostics (MSD)) was used as described previously<sup>94</sup>: the plate was blocked by adding Diluent 35 (provided by the manufacturer) for 60 min, followed by a wash with 0.05% Tween 20 in PBS, pH 7.6. TBS and Triton-X fractions were used undiluted, whereas the SDS fraction was diluted 1:500 in Diluent 35. Each sample was added to a well supplemented with a detection antibody solution containing 2% 50 $\times$  SULFO-TAG 6E10 detection antibody and 1% A $\beta$ 40 blocker in Diluent 100. The plate was read using an MS6000 machine (MSD). For murine brain tissue, TBS, Triton-X and SDS fractions were analyzed, whereas, for human tissue, TX and SDS fractions were assessed.

### Lipidomics

Compound extraction was performed using a mixture of methanol, methyl tert-butyl ether and chloroform (MMC, 4:3:3, v/v/v)<sup>95</sup>. The MMC solvent was supplemented with SPLASH LIPIDOMIX standard and additional internal standards, d7-sphinganine (SPH d18:0), d7-sphingosine (SPH d18:1), dihydroceramide (Cer d18:0/12:0), ceramide (Cer d18:1/12:0), deoxydihydroceramide (Cer m18:0 12:0) deoxyceramide (Cer m18:1 12:0) and glucosylceramides (GluCer d18:1/8:0 and GlcCer d18:1 18:1 (d5)) (Avanti Polar Lipids). Liquid chromatography was carried out as described previously<sup>96</sup> with

some modifications. Lipids were separated using a C30 Accucore LC column (150 mm  $\times$  2.1 mm, 2.6- $\mu\text{m}$  particle size) and a Transcend UHPLC pump (Thermo Fisher Scientific). Mass spectrometry analysis was done on a hybrid quadrupole-orbitrap mass spectrometer (Thermo Fisher Scientific, Q-Exactive). Mass spectra were acquired with a resolution accuracy of 5 ppm from predicted masses at a resolving power of 70,000 at 200  $m/z$ . Positive and negative ionization modes were acquired alternately. Data analysis was performed using Compound Discoverer 3.3.2.31 (Thermo Fisher Scientific) for retention time alignment, peak picking, annotation and matching to the metabolite databases LipidBlast VS68 and Metlin Experimental Mass Spectral Database, version 2017 (Scripps Center for Metabolomics)<sup>96,97</sup>. The web-based platform MetaboAnalyst (<https://www.metaboanalyst.ca>) was used to analyze the lipidomics data. With the integrated Statistical Analysis module, heatmaps and partial least squares-discriminant analysis (PLS-DA) were generated and visualized.

### Human postmortem CNS tissue gene and protein expression analyses

Patients with AD were stratified by the 'ABC' score for AD neuropathology as defined by Montine et al.<sup>98</sup>. Hippocampal tissue was homogenized using a Pellet Mixer (VWR, 431-0100) in 0.30 ml of RLT lysis buffer provided in the RNA purification kit (Qiagen, 74004) and subsequently passing the homogenate through a 23-gauge needle (B. Braun, 465766) until no clumps remained. RNA was isolated according to the manufacturer's protocol and eluted in 18  $\mu\text{l}$  of RNase-free water. cDNA was generated using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, 4368813). qPCR was performed by TaqMan Fast Universal Master (Thermo Fisher Scientific, 4364103) and primers *Il12rb* (Thermo Fisher Scientific, Hs00155486\_m1), *Il23r* (Thermo Fisher Scientific, Hs00332759\_m1) and GAPDH (Thermo Fisher Scientific, Hs02786624\_g1) on QuantStudio 6 Flex (Applied Biosystems) were used. Gene transcriptional level was analyzed using CT values by the  $\Delta\Delta\text{CT}$  method<sup>99</sup>. Human protein extraction was performed in the same fashion as for mouse brain tissue (see above). For IL12p70 measurements, the soluble TBS fraction was used, and IL12p70 was measured using a human IL12p70-specific high-sensitivity ELISA (Thermo Fisher Scientific, BMS238HS) according to the manufacturer's instructions.

### Myelinating mouse spinal cord and primary oligodendrocyte cell cultures

Oligodendrocytes and neurofilaments were cultured from embryonic day 13 (E13) mouse spinal cords as described by Thomson et al.<sup>100</sup>. Cultures were supplemented with insulin until 12 days in vitro (DIV12), followed by adding IL-12p70 (10 ng ml<sup>-1</sup>, recombinant murine IL-12 p70, 210-12; PeproTech), IL-12p80 (5 ng ml<sup>-1</sup>, recombinant murine IL-12 p80, 210-12P80H; PeproTech) or vehicle to the medium for the indicated duration. Primary oligodendrocytes were sorted via magnetic-activated cell sorting (MACS) using O4 beads and cultivated for 5 days until treatment with either IL-12p70 (10 ng ml<sup>-1</sup>, recombinant murine IL-12 p70, 210-12; PeproTech) or IL-12p80 (5 ng ml<sup>-1</sup>, recombinant murine IL-12 p80, 210-12P80H; PeproTech). Myelinating cultures were harvested at DIV30. Cells on coverslips were fixed with 4% PFA for 10 min and washed with PBS before permeabilization with 0.5% Triton-X in PBS. Unspecific binding was blocked using 10% normal goat serum in PBS, and primary antibodies recognizing MBP (rat, MCA409S, 1:200; Bio-Rad) and neurofilament (mouse, 837904, 1:500; BioLegend) were added and incubated overnight at 4 °C. Secondary antibodies (Alexa Fluor 488 goat anti-rat, 112-545-003, 1:300; Dianova and Alexa Fluor 647 donkey anti-mouse, A31571, 1:300; Invitrogen) were added and incubated for 1 h at room temperature. Cells were counterstained with DAPI as described above (see 'Immunohistochemical stainings, quantitative assessment and microglial phagocytosis assay' subsection).



### Human oligodendrocyte-like cell cultures

The human oligodendrogloma cell line (Sigma-Aldrich, SCC163) was cultured in growth medium (GM) (DMEM, high-glucose D6546-6X500ML, Thermo Fisher Scientific; 10% FCS, 1% penicillin–streptomycin and 1% L-glutamin). For differentiation, 100,000 cells per six wells were plated in differentiation medium (DM) (DMEM (D6546-6X500ML, Thermo Fisher Scientific), 0.05% FCS, 1% penicillin–streptomycin, 1% Insulin-Transferrin-Selenium (ITS-G) (Thermo Fisher Scientific, 41400045) and 30 nM 3,3',5-triiodo-L-thyronin (Merck, T-074-1ML)) for 2 days. As a control, 100,000 cells per six wells were plated in GM. After 2 days, DM was supplemented with 10 ng ml<sup>-1</sup> FGF-2 and 10 ng ml<sup>-1</sup> PDGF-AA and matured for an additional day while cells in GM were fed with GM. After 3 days, cells grown in GM reached 100% confluency, whereas cells grown in DM were at approximately 30% confluency. Next, oligodendrocytes were stimulated in GM with 85 nM or 1.5 nM IL-12p70, IL-12p80 or IL-23 dissolved in 0.25% BSA in PBS for 24 h as depicted in Extended Data Fig. 5e–i. Control wells (vehicle-treated) were stimulated with 0.25% BSA in PBS. For qPCR, cells were harvested, and RNA was isolated using the Qiagen miRNA kit according to the manufacturer's instructions. MBP qPCR was performed by TaqMan Fast Universal Master (Thermo Fisher Scientific, 4364103) using primers MBP (Thermo Fisher Scientific, Hs00921945\_m1) and GAPDH (Thermo Fisher Scientific, Hs02786624\_g1) on QuantStudio 6 Flex (Applied Biosystems). Gene transcriptional levels were analyzed using CT values by the  $\Delta\Delta CT$  method<sup>99</sup>. Cytokines were measured using a V-Plex Cytokine Panel 1 Human Kit (MSD, K15959D-1) on an MS6000 machine (MSD).

### Statistics and reproducibility

As for in vitro data, at least two independent experiments were performed with at least three technical replicates per condition. Sample sizes were chosen based on previous experiments, and no statistical method was used to predetermine sample size for all experiments. For immunohistochemical stainings, an *n* of 6 per genotype was chosen; for biochemical (Meso Scale) as well as lipidomics analyses, an *n* of 8 was chosen. For snRNA-seq analyses an *n* of 3 per genotype was taken. The investigators were blinded during image acquisition and analysis. All data were checked for normal distribution before choosing the appropriate statistical test.

For the identification of differentially regulated gene expression in snRNA-seq data, we removed the *Ttr* gene as its expression was highly dependent on the presence of a choroid plexus cluster in a given sample, suggesting a bias due to the dissection at the stage of hippocampus isolation (indicated in the Methods section).

When performing the 6E10 A $\beta$  Triplex Assay using protein extraction generated from the brains of APPPS1.NestinCre.*IL23r*<sup>fl/fl</sup> animals, a few readings generated the output 'NaN' due to a technical error. The individual data points, which represented non-available values, were excluded in subsequent analyses and explains the fewer data points in Fig. 1e.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

The raw sequencing and processed data are available in the Gene Expression Omnibus under accession number [GSE173242](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE173242), and a shiny app was created, which allows access to single-nucleus data for any gene of interest interactively via the following URL: [https://shiny.mdc-berlin.de/AD\\_Neuroinflammation/](https://shiny.mdc-berlin.de/AD_Neuroinflammation/). Lipidomics data for re-analysis are available in a Zenodo repository at <https://doi.org/10.5281/zenodo.14620944>. Source data and immunohistochemical image files will be provided upon reasonable request.

### Code availability

Codes for snRNA-seq data are available at [https://github.com/m21camby/AD\\_Neuroinflammation](https://github.com/m21camby/AD_Neuroinflammation). Codes for microglia workflow are available at <https://github.com/ngimber/AlzheimersWorkflow>.

### References

- Guerreiro, R. J. et al. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. *Neurodegener. Dis.* **4**, 406–412 (2007).
- Heinzel, F. P., Hujer, A. M., Ahmed, F. N. & Nerke, R. M. In vivo production and function of IL-12 p40 homodimers. *J. Immunol.* **158**, 4381–4388 (1997).
- Tait Wojno, E. D., Hunter, C. A. & Stumhofer, J. S. The immunobiology of the interleukin-12 family: room for discovery. *Immunity* **50**, 851–870 (2019).
- Gately, M. K. et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. *Annu. Rev. Immunol.* **16**, 495–521 (1998).
- Presky, D. H. et al. A functional interleukin 12 receptor complex is composed of two  $\beta$ -type cytokine receptor subunits. *Proc. Natl Acad. Sci. USA* **24**, 14002–14007 (1996).
- Zou, J. et al. Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits  $\beta 1$  and  $\beta 2$  and JAK kinases. *J. Biol. Chem.* **9**, 6073–6077 (1997).
- Vom Berg, J. et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. *Nat. Med.* **18**, 1812–1819 (2012).
- Eede, P. et al. Interleukin-12/23 deficiency differentially affects pathology in male and female Alzheimer's disease-like mice. *EMBO Rep.* **21**, e48530 (2020).
- Trinchieri, G., Pflanz, S. & Kastelein, R. A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. *Immunity* **19**, 641–644 (2003).
- Hawrylycz, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature* **489**, 391–399 (2012).
- Halliday, G. Pathology and hippocampal atrophy in Alzheimer's disease. *Lancet Neurol.* **16**, 862–864 (2017).
- Zeisel, A. et al. Molecular architecture of the mouse nervous system. *Cell* **174**, 999–1014 (2018).
- Saunders, A. et al. Molecular diversity and specializations among the cells of the adult mouse brain. *Cell* **174**, 1015–1030 (2018).
- Erö, C., Gewaltig, M. O., Keller, D. & Markram, H. A cell atlas for the mouse brain. *Front. Neuroinform.* **12**, 84 (2018).
- Keller, D., Erö, C. & Markram, H. Cell densities in the mouse brain: a systematic review. *Front. Neuroanat.* **12**, 83 (2018).
- Wang, X., Park, J., Susztak, K., Zhang, N. R. & Li, M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. *Nat. Commun.* **10**, 380 (2019).
- Safaiyan, S. et al. Age-related myelin degradation burdens the clearance function of microglia during aging. *Nat. Neurosci.* **19**, 995–998 (2016).
- Peters, A. The effects of normal aging on myelinated nerve fibers in monkey central nervous system. *Front. Neuroanat.* **3**, 11 (2009).
- Xing, Y. et al. Age-related changes of myelin basic protein in mouse and human auditory nerve. *PLoS ONE* **7**, e34500 (2012).
- Edgar, J. M. et al. Río-Hortega's drawings revisited with fluorescent protein defines a cytoplasm-filled channel system of CNS myelin. *J. Anat.* **239**, 1241–1255 (2021).
- Buntinx, M. et al. Characterization of three human oligodendroglial cell lines as a model to study oligodendrocyte injury: morphology and oligodendrocyte-specific gene expression. *J. Neurocytol.* **32**, 25–38 (2003).
- Pelkey, K. A. et al. Hippocampal GABAergic inhibitory neurons. *Physiol. Rev.* **97**, 1619–1747 (2017).

23. Xu, Y., Zhao, M., Han, Y. & Zhang, H. GABAergic inhibitory interneuron deficits in Alzheimer's disease: implications for treatments. *Front. Neurosci.* **14**, 660 (2020).
24. Carlesimo, G. A. et al. Atrophy of presubiculum and subiculum is the earliest hippocampal anatomical marker of Alzheimer's disease. *Alzheimers Dement. (Amst.)* **1**, 24–32 (2015).
25. Tian, J. et al. Down-regulation of neuregulin1/ErbB4 signaling in the hippocampus is critical for learning and memory. *Mol. Neurobiol.* **54**, 3976–3987 (2017).
26. Goodman, A. B. & Pardee, A. B. Evidence for defective retinoid transport and function in late onset Alzheimer's disease. *Proc. Natl Acad. Sci. USA* **100**, 2901–2905 (2003).
27. Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand–receptor complexes. *Nat. Protoc.* **15**, 1484–1506 (2020).
28. Erskine, L. et al. VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm. *Neuron* **70**, 951–965 (2011).
29. Roy, S. et al. Multifaceted role of neuropilins in the immune system: potential targets for immunotherapy. *Front. Immunol.* **8**, 1228 (2017).
30. Flores, A. I. et al. Akt-mediated survival of oligodendrocytes induced by neuregulins. *J. Neurosci.* **20**, 7622–7630 (2000).
31. Brinkmann, B. G. et al. Neuregulin-1/ErbB signaling serves distinct functions in myelination of the peripheral and central nervous system. *Neuron* **59**, 581–595 (2008).
32. Depp, C. et al. Myelin dysfunction drives amyloid- $\beta$  deposition in models of Alzheimer's disease. *Nature* **618**, 349–357 (2023).
33. Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer's disease. *Cell* **169**, 1276–1290 (2017).
34. Thrupp, N. et al. Single-nucleus RNA-seq is not suitable for detection of microglial activation genes in humans. *Cell Rep.* **32**, 108189 (2020).
35. Ndoja, A. et al. Ubiquitin ligase COP1 suppresses neuro-inflammation by degrading c/EBP $\beta$  in microglia. *Cell* **182**, 1156–1169.e12 (2020).
36. Idda, M. L., Munk, R., Abdelmohsen, K. & Gorospe, M. Noncoding RNAs in Alzheimer's disease. *Wiley Interdiscip. Rev. RNA* <https://doi.org/10.1002/wrna.1463> (2018).
37. Li, Y., Li, Q., Wang, C., Li, S. & Yu, L. Long noncoding RNA expression profile in BV2 microglial cells exposed to lipopolysaccharide. *Biomed. Res. Int.* **2019**, 5387407 (2019).
38. Zhang, P., Cao, L., Zhou, R., Yang, X. & Wu, M. The lncRNA *Neat1* promotes activation of inflammasomes in macrophages. *Nat. Commun.* **10**, 1495 (2019).
39. Feng, F., Qi, Y., Dong, C. & Yang, C. PVT1 regulates inflammation and cardiac function via the MAPK/NF- $\kappa$ B pathway in a sepsis model. *Exp. Ther. Med.* **16**, 4471–4478 (2018).
40. Lee, E. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. *J. Exp. Med.* **199**, 125–130 (2004).
41. Andreadou, M. et al. IL-12 sensing in neurons induces neuroprotective CNS tissue adaptation and attenuates neuroinflammation in mice. *Nat. Neurosci.* **26**, 1701–1712 (2023).
42. Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. *Immunity* **47**, 566–581 (2017).
43. Kim, B. et al. TREM2 risk variants are associated with atypical Alzheimer's disease. *Acta Neuropathol.* **144**, 1085–1102 (2022).
44. Castellano, J. et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. *Nature* **544**, 488–492 (2017).
45. Croxford, A. L. et al. The cytokine GM-CSF drives the inflammatory signature of CCR2<sup>+</sup> monocytes and licenses autoimmunity. *Immunity* **43**, 502–514 (2015).
46. Nasrabady, S. E., Rizvi, B., Goldman, J. E. & Brickman, A. M. White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. *Acta Neuropathol. Commun.* **6**, 22 (2018).
47. Dong, Y. X. et al. Association between Alzheimer's disease pathogenesis and early demyelination and oligodendrocyte dysfunction. *Neural Regen. Res.* **13**, 908–914 (2018).
48. Desai, M. K. et al. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. *Am. J. Pathol.* **177**, 1422–1435 (2010).
49. Chen, J. F. et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer's disease. *Neuron* **109**, 2292–2307 (2021).
50. Quintela-López, T. et al. A $\beta$  oligomers promote oligodendrocyte differentiation and maturation via integrin  $\beta$ 1 and Fyn kinase signaling. *Cell Death Dis.* **10**, 445 (2019).
51. Behrendt, G. et al. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. *Glia* **61**, 273–286 (2013).
52. Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. *Nat. Med.* **26**, 131–142 (2020).
53. Lindberg, O. et al. Atrophy of the posterior subiculum is associated with memory impairment, tau- and A $\beta$  pathology in non-demented individuals. *Front. Aging Neurosci.* **9**, 306 (2017).
54. Brickman, A. M. Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. *Curr. Neurol. Neurosci. Rep.* **13**, 415 (2013).
55. Gouw, A. A. et al. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. *Brain* **131**, 3286–3298 (2008).
56. Desai, M. K., Guercio, B. J., Narrow, W. C. & Bowers, W. J. An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction. *Glia* **59**, 627–640 (2011).
57. Mitew, S. et al. Focal demyelination in Alzheimer's disease and transgenic mouse models. *Acta Neuropathol.* **119**, 567–577 (2010).
58. Yang, C. et al. STAT4: an immunoregulator contributing to diverse human diseases. *Int. J. Biol. Sci.* **16**, 1575–1585 (2020). Mar 5.
59. Vartanian, T., Li, Y., Zhao, M. & Stefansson, K. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. *Mol. Med.* **1**, 732–743 (1995).
60. Panuccio, G., Vicini, S. & Avoli, M. Cell type-specific properties of subicular GABAergic currents shape hippocampal output firing mode. *PLoS ONE* **7**, e50241 (2012).
61. Zhang, P. et al. NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation. *Cell Death Dis* **14**, 159 (2023).
62. Mei, L. & Nave, K. A. Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. *Neuron* **83**, 27–49 (2014).
63. López-Bendito, G. et al. Tangential neuronal migration controls axon guidance: a role for neuregulin-1 in thalamocortical axon navigation. *Cell* **125**, 127–142 (2006).
64. Mei, L. & Xiong, W. C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. *Nat. Rev. Neurosci.* **9**, 437–452 (2008).
65. Radde, R. et al. A $\beta$ 42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. *EMBO Rep.* **7**, 940–946 (2006).
66. Magram, J. et al. IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. *Ann. N.Y. Acad. Sci.* **795**, 60–70 (1996).

67. Zwicky, P. et al. IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation. *Sci. Immunol.* **6**, eabg9012 (2021).
68. Tronche, F. et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. *Nat. Genet.* **23**, 99–103 (1999).
69. Giusti, S. A. et al. Behavioral phenotyping of Nestin-Cre mice: implications for genetic mouse models of psychiatric disorders. *J. Psychiatr. Res.* **55**, 87–95 (2014).
70. Aden, K. et al. Epithelial IL-23R signaling licenses protective IL-22 responses in intestinal inflammation. *Cell Rep.* **16**, 2208–2218 (2016).
71. Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. *Nat. Biotechnol.* **33**, 495–502 (2015).
72. Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. *Cell Syst.* **8**, 281–291 (2019).
73. Praktijnjo, S. D. et al. Tracing tumorigenesis in a solid tumor model at single-cell resolution. *Nat. Commun.* **11**, 991 (2020).
74. Soneson, C. & Robinson, M. D. Bias, robustness and scalability in single-cell differential expression analysis. *Nat. Methods* **15**, 255–261 (2018).
75. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2009).
76. Alexa, A., Rahnenführer, J. & Lengauer, T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. *Bioinformatics* **22**, 1600–1607 (2006).
77. Schlitzer, A. et al. Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. *Nat. Immunol.* **16**, 718–728 (2015).
78. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).
79. Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J. & Prins, P. Sambamba: fast processing of NGS alignment formats. *Bioinformatics* **31**, 2032–2034 (2015).
80. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
81. Kent, W. J., Zweig, A. S., Barber, G., Hinrichs, A. S. & Karolchik, D. BigWig and BigBed: enabling browsing of large distributed datasets. *Bioinformatics* **26**, 2204–2207 (2010).
82. Bakken, T. E. et al. Comparative cellular analysis of motor cortex in human, marmoset and mouse. *Nature* **598**, 111–119 (2021).
83. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
84. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
85. Li, H. D. GTFtools: a Python package for analyzing various modes of gene models. Preprint at *bioRxiv* <https://doi.org/10.1101/263517> (2018).
86. Weil, M.-T., Ruhwedel, T., Meschkat, M., Sadowski, B. & Möbius, W. Transmission electron microscopy of oligodendrocytes and myelin. In *Oligodendrocytes: Methods and Protocols* (eds Lyons, D. A. & Kegel, L.) 343–375 (Springer, 2019).
87. Schultz, R. L. & Karlsson, U. Fixation of the central nervous system for electron microscopy by aldehyde perfusion. II. Effect of osmolarity, pH of perfusate, and fixative concentration. *J. Ultrastruct. Res.* **12**, 187–206 (1965).
88. Van Tilborg, E. et al. A quantitative method for microstructural analysis of myelinated axons in the injured rodent brain. *Sci. Rep.* **7**, 16492 (2017).
89. Krabbe, G. et al. Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. *Brain Behav. Immun.* **26**, 419–428 (2012).
90. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671–675 (2012).
91. Gimber, N. AlzheimersWorkflow. *GitHub* <https://github.com/ngimber/AlzheimersWorkflow> (2024).
92. Schmidt, U., Weigert, M., Broaddus, C., & Myers, G. Cell detection with star-convex polygons. In *Proc. International Conference on Medical Image Computing and Computer-Assisted Intervention* (eds Frangi, A. F., Schnabel, J. A., Davatzikos, C., Alberola-López, C. & Fichtinger, G.) [https://doi.org/10.1007/978-3-030-00934-2\\_30](https://doi.org/10.1007/978-3-030-00934-2_30) (Springer, 2018).
93. Blennow, K. et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat. Rev. Neurol.* **6**, 131–144 (2010).
94. Pellegrino, R. M., Di Veroli, A., Valeri, A., Goracci, L. & Cruciani, G. LC/MS lipid profiling from human serum: a new method for global lipid extraction. *Anal. Bioanal. Chem.* **406**, 7937–7948 (2014).
95. Narvaez-Rivas, M. & Zhang, Q. Comprehensive untargeted lipidomic analysis using core-shell C30 particle column and high field orbitrap mass spectrometer. *J. Chromatogr. A* **1440**, 123–134 (2016).
96. Kind, T. et al. LipidBlast in silico tandem mass spectrometry database for lipid identification. *Nat. Methods* **10**, 755–758 (2013).
97. Tautenhahn, R. et al. An accelerated workflow for untargeted metabolomics using the METLIN database. *Nat. Biotechnol.* **30**, 826–828 (2012).
98. Montine, T. J. et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. *Acta Neuropathol.* **123**, 1–11 (2012).
99. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C_T}$  method. *Methods* **25**, 402–408 (2001).
100. Thomson, C. E. et al. Myelinated, synapsing cultures of murine spinal cord—validation as an in vitro model of the central nervous system. *Eur. J. Neurosci.* **28**, 1518–1535 (2008).

## Acknowledgements

We are indebted to E. Benke, A. Förster and A. Haake (Department of Neuropathology, Charité – Universitätsmedizin Berlin, Germany) for excellent technical assistance and advice. Nestin<sup>Cre</sup> animals for breeding were kindly provided by J. Priller (Department of Psychiatry and Neurosciences, Charité – Universitätsmedizin Berlin, Germany). Cartoon images were partially created with BioRender. We thank A. Alkin, M. Landthaler and L. Haghverdi (BIMSB, MDC, Berlin, Germany) for advice. We thank C. Cerda Jara, A. Rybak-Wolf, M. Wandres and A. Löwa (all BIMSB, MDC, Berlin, Germany) for fruitful discussions. We thank S. Praktijnjo and B. Obermayer (BIMSB, MDC, and BIH Berlin, Germany) for providing codes of entropy analysis. We thank the Advanced Medical BioImaging Core Facility of the Charité – Universitätsmedizin Berlin (AMBIO) for support in acquiring and analyzing the imaging data. This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy NeuroCure – EXC-2049 – 390688087 to N.R. and F.L.H. as well as SFB TRR 167 and HE 3130/6-1 to F.L.H.; the German Center for Neurodegenerative Diseases (DZNE) Berlin (F.L.H.); the European Union (PHAGO, 115976, Innovative Medicines Initiative-2 to F.L.H.); and the Swiss National Science Foundation (Ambizione grant PZ00P3\_193330 to S.M.). S.M. was supported by the University of Zurich Forschungskredit (K-41302-11-01). S.S. was funded by a PhD fellowship from the NeuroCure Excellence Cluster EXC-2049. S.J.K. was funded by the European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie grant agreement

number 721890 (circRTrain ITN). N.K. was supported by the grant DFG/GZ: KA 5006/1-1. K.-A.N. was funded by the ERC Advanced Grant MyelinANO and by the SFB TRR274 (DFG). J.M.E. is funded by the UK MS Society (grant 127) and NC3Rs grant reference NC/TO02247/1. S.P. was supported by the National Institutes of Health (P30 AG047266), the Florida Department of Health (FL DOH 21A10) and the Charlotte and Howard Zimmerman Rising Star Professorship with the Norman Fixel Institute for Neurological Diseases. N.G. was supported by DFG grant SFB958/Z02 to J.S.

## Author contributions

S.S., P.E., A.B., M.F., C.B., M.J., J.O. and M.G. performed experiments, and C.K., J.M.E., F.L.H. and N.R. supervised experiments. S.J.K. performed bioinformatics analyses, and N.R. and N.K. supervised bioinformatics analyses. M.A., S.M. and B.B. generated the IL12Rb2 LoxP mouse line. S.P. provided human tissue. W.M., T.R. and K.-A.N. designed ultrastructural analyses; T.R. recorded and processed electron microscopy images; and M.G. analyzed them. A.H. and T.H. performed mass spectrometry and processed the data, and M.G. analyzed them. N.G. and J.S. contributed to and supervised the image analysis. W.K. and T.J. supported cell culture experiments. All authors contributed to the experiments and supported data analyses. N.R. and F.L.H. designed the study and procured funding. C.K., N.R. and F.H. jointly supervised the study. S.J.K., S.S. and M.G. prepared figures. S.S., S.J.K., P.E., B.B., M.A., N.K., C.K., K.-A.N., W.M., T.R., E.F., M.G., N.R. and F.L.H. wrote and revised the manuscript. All authors approved the manuscript.

## Funding Information

Open access funding provided by Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC).

## Competing interests

All authors declare that they have no competing interests.

## Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s43587-025-00816-2>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s43587-025-00816-2>.

**Correspondence and requests for materials** should be addressed to Nikolaus Rajewsky or Frank L. Heppner.

**Peer review information** *Nature Aging* thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025, corrected publication 2025

**Shirin Schneeberger<sup>1,21</sup>, Seung Joon Kim<sup>2,21</sup>, Maria N. Geesdorf<sup>1,21</sup>, Ekaterina Friebel<sup>1</sup>, Pascale Eede<sup>1</sup>, Marina Jendrach<sup>1</sup>, Anastasiya Boltengagen<sup>2</sup>, Caroline Braeuning<sup>3</sup>, Torben Ruhwedel<sup>4,5</sup>, Andreas J. Hülsmeier<sup>6</sup>, Niclas Gimber<sup>7</sup>, Marlene Foerster<sup>1</sup>, Juliane Obst<sup>1</sup>, Myrto Andreadou<sup>8</sup>, Sarah Mundt<sup>8</sup>, Jan Schmoranzner<sup>7</sup>, Stefan Prokop<sup>9,10,11,12</sup>, Wiebke Kessler<sup>13</sup>, Tanja Kuhlmann<sup>13</sup>, Wiebke Möbius<sup>4,5</sup>, Klaus-Armin Nave<sup>4</sup>, Thorsten Hornemann<sup>6</sup>, Burkhard Becher<sup>8</sup>, Julia M. Edgar<sup>14</sup>, Nikos Karaiskos<sup>15</sup>, Christine Kocks<sup>16</sup>, Nikolaus Rajewsky<sup>2,15,16,17,18,19,21</sup> & Frank L. Heppner<sup>1,15,20,21</sup>**

<sup>1</sup>Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. <sup>2</sup>Systems Biology of Gene Regulatory Elements, Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. <sup>3</sup>Genomics Platform, Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. <sup>4</sup>Department of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany. <sup>5</sup>Department of Neurogenetics, Electron Microscopy Unit City Campus, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany. <sup>6</sup>Institute of Clinical Chemistry, University of Zürich, Zürich, Switzerland. <sup>7</sup>AMBIO Advanced Medical Bioimaging Core Facility, Charité – Universitätsmedizin Berlin, Berlin, Germany. <sup>8</sup>Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. <sup>9</sup>Department of Pathology, College of Medicine, University of Florida, Gainesville, FL, USA. <sup>10</sup>Evelyn F. and William L. McKnight Brain Institute, University of Florida, Gainesville, FL, USA. <sup>11</sup>Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA. <sup>12</sup>Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA. <sup>13</sup>Institute of Neuropathology, University Hospital Münster, Münster, Germany. <sup>14</sup>School of Infection and Immunity, University of Glasgow, Glasgow, UK. <sup>15</sup>Cluster of Excellence, NeuroCure, Berlin, Germany. <sup>16</sup>German Cancer Consortium (DKTK), Heidelberg, Germany. <sup>17</sup>German Center for Cardiovascular Research (DZHK), Berlin, Germany. <sup>18</sup>National Center for Tumor Diseases (NCT), Berlin, Germany. <sup>19</sup>Charité – Universitätsmedizin, Berlin, Germany. <sup>20</sup>German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany. <sup>21</sup>These authors contributed equally: Shirin Schneeberger, Seung Joon Kim, Maria N. Geesdorf, Nikolaus Rajewsky, Frank L. Heppner.


✉ e-mail: [rajewsky@mdc-berlin.de](mailto:rajewsky@mdc-berlin.de); [frank.heppner@charite.de](mailto:frank.heppner@charite.de)



Extended Data Fig. 1 | See next page for caption.


**Extended Data Fig. 1 | Human IL-12/IL-23 receptor expression and mouse snRNA-seq data quality and cluster annotation.** Single-nucleus transcriptome data of 76,533 total nuclei isolated from two postmortem human primary motor cortex derived from [portal.brainmap.org](http://portal.brainmap.org) 4. **a-c.** Violin plots showing captured *IL12RB1*, *IL12RB2* and *IL23R* transcripts per cell type in the human cortex. **d,e.** Violin plots depicting various murine hippocampal cell types: gene count per cell (**d**) and UMI count per cell (**e**), averaging at 1,412 genes and 2,421 UMI, respectively. **f-h.** Doublet discrimination identified roughly 5% of all nuclei as

doublets. From a total of 44 detected clusters, cluster 25, 31, 33, 34, 41, 42, 42 and 44 were flagged as clusters carrying doublets using Scrublet (v.0.21). Clusters with >50% of doublets were removed from further analysis. **i.** Bar graph depicting biotypes of detected RNA shows that approximately 85.7% of all transcripts were protein-coding followed by 13.4% long non-coding RNAs (lncRNAs). **j.** Heatmap showing cell type-specific lncRNAs. **k.** Cellular proportions of our snRNA-seq mouse study reflected the **l.** published cellular composition of the hippocampus according to the Blue Brain Cell Atlas.



**Extended Data Fig. 2 | Absence of major batch effects in hippocampal snRNA-seq data from 250-day old mice.** **a.** UMAP visualization of three individual biological replicates per genotype, showing mostly equal representations in each cluster. **b-d.** Entropy-based quantification of batch effects. The distribution of relative entropy values for cells of three individual biological replicates per genotype grouped by sample (original identity) or genotype was greater than randomizing these labels across cells (**b**). **c-d.** Different cell types grouped by genotype (**c**) and sample (**d**) (original identity); boxplots show: middle, median;

lower hinge, 25% quantile; upper hinge, 75% quantile; upper/lower whisker, largest/smallest observation less/greater than or equal to upper/lower hinge  $\pm 1.5 \times$  IQR. Relative entropy per cell type was highest for cell types that differed biologically between genotypes, for example microglia and oligodendrocytes which react most strongly to amyloid and inflammatory conditions. Thus, differences were driven by biological meaningful distinctions rather than technical errors.




Extended Data Fig. 3 | See next page for caption.




**Extended Data Fig. 3 | Various snRNA-seq and bulk RNA-seq analyses in 250-day-old mice reveal no significant changes in cell types other than oligodendrocytes and neurons.** **a.** Correlation of hippocampal snRNA-seq and bulk RNA-seq data with respect to the ratio in appearance of distinct cell types ( $r \geq 0.75$ ). **b.** Principal component analysis of biological replicates (bulk RNA-seq), each replicate is represented by one dot. WT mice cluster together, while APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> mice are more scattered. **c-d.** MA plots comparing bulk gene expression of APPPS1 vs. WT mice (**c**) and of APPPS1.*Il12b*<sup>-/-</sup> vs. APPPS1 mice (**d**). **e.** Close-up of the astrocyte gene signatures derived from single-nucleus RNA-seq of WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> mice. **f.** Density plots illustrating the distribution of overall captured transcripts in WT vs. APPPS1 and APPPS1 vs. APPPS1.*Il12b*<sup>-/-</sup> mice. **g.** Feature plot of the distribution of *Gfap* transcripts in the astrocyte cluster and **h.** *Gfap* expression levels in WT, APPPS1 and APPPS1.*Il12b*<sup>-/-</sup>. **i.** Comparison of cellular proportions of three biological replicates per genotype determined by three independent methods, namely the previously published

reference data set (red), snRNA-seq (green) and deconvolution of bulk RNA-seq data (dark blue). Of note, the deconvolution matched the other two reference data sets best in OPCs, microglia and oligodendrocytes. Boxplots show: middle, median; lower hinge, 25% quantile; 45 upper hinge, 75% quantile; upper/lower whisker, largest/smallest observation less/greater than or equal to upper/lower hinge  $\pm 1.5 \times$  IQR. **j.** Cellular proportions gathered from deconvoluted bulk RNA-seq data across all three genotypes with three biological replicates each showed enhanced numbers of microglia in APPPS1 and APPPS1.*Il12b*<sup>-/-</sup> mice and a rescue of oligodendrocytes numbers in APPPS1.*Il12b*<sup>-/-</sup> mice. All  $df = 2$ ,  $F = 6.053$  for neurons,  $F = 3.783$  for astrocytes,  $F = 83.238$  for microglia,  $F = 26.317$  for oligodendrocytes,  $F = 6.216$  for OPCs,  $F = 7.182$  for vascular cells,  $F = 0.499$  for rest. One-way ANOVA with Holm-Bonferroni  $P$  value adjustment; boxplots show: middle, median; lower hinge, 25% quantile; upper hinge, 75% quantile; upper/lower whisker, largest/smallest observation less/greater than or equal to upper/lower hinge  $\pm 1.5 \times$  IQR.



**Extended Data Fig. 4 | Differential gene expression of oligodendrocyte developmental states show unchanged OPC to oligodendrocyte maturation in amyloid-carrying APPPS1 mice. a,b,c.** Volcano plots showing differentially regulated genes across all genotypes in MOL (a), MFOL (b) and OPC (c).


Pseudotime analysis for genes involved in positive regulation (GO:0048714) of oligodendrocyte maturation (d-e) and negative regulation (GO:0048715) of oligodendrocyte maturation (f-g) show no strong difference across genotypes.



Extended Data Fig. 5 | See next page for caption.


**Extended Data Fig. 5 | IL-12-dependent status of murine oligodendrocytes and of matured human-oligodendrocyte-like cells.** **a.** Gene Ontology (GO) of differentially expressed transcripts of different types of oligodendrocytes derived from APPPS1 vs. APPPS1.*IL12b*<sup>-/-</sup> mice. Dot size illustrates gene ratio, color denotes *P* value. One-way ANOVA with Holm Bonferroni *P* value adjustment. **b.** Violin plot depicting log<sub>2</sub>-fold changes in expression of distinct genes of the analysis shown in (a). Red dots indicate genes with positive log<sub>2</sub>-fold changes, blue dots those with negative log<sub>2</sub>-fold changes. **c.** MBP-immunoreactivity in the cortex of APPPS1 and APPPS1.*IL12b*<sup>-/-</sup> versus WT control. Scale bar: 100 μm. **d.** Quantification of MBP-covered area, *n* = 6 biological replicates per genotype, one-way ANOVA showed no significant differences. **e.** Cartoon illustrating human oligodendroglioma (HOG) cell maturation. **f.** qPCR of differentiated HOG cell line exemplifying oligodendrocyte-like cells versus non-differentiated HOG cells show a maturation-dependent increase in MBP expression, *n* = 3 technical

replicates, Student's *t*-test, *P* = 0.0178. **g.** Statistical analysis using two-tailed unpaired students *t*-test, *t* = 3.885, *df* = 4, *n* = 3 technical replicates. **h.** Maturation/differentiation-dependent increase in the expression of various pro-inflammatory cytokines in the supernatant of HOG upon stimulation with 85 nM IL-12p70, 85 nM IL-12p80 or vehicle only. Undifferentiated HOG cells are shown in green squares, differentiated HOG cells are in blue squares. All *df* = 17. *F* = 19.70 for IL-7, *F* = 85.55 for TNF-β, *F* = 876.8 for VEGFA, *F* = 155.2 for IL-17, *F* = 117.4 for IL-1a, *F* = 232.2 for IL-16, *n* = 3 technical replicates. **i.** Even doses as low as 1.5 nM IL-12p70 or 1.5 nM IL-12p80 suffice to induce cytokine expression in differentiated HOG cells, while 1.5 nM IL-23 has almost no effect. All *df* = 11, *F* = 73.8 for IL-15, *F* = 12.7 for TNF-β, *F* = 67.3 for IL-1a, *F* = 79.2 for IL-16, *F* = 10.5 for VEGFA. Analyzed by one-way ANOVA with Tukey's multiple-comparisons test. Each dot represents one technical replicate (*n* = 3). Bars represent mean ± s.e.m.



**Extended Data Fig. 6 | IL-12 signaling leads to transcriptional changes in neurons.** **a**, Subicular neurons appeared to be somewhat reduced in APPPS1 and APPPS1.*II12b*<sup>-/-</sup> mice when compared to WT mice. All *df* = 2, *F* = 0.161 for dentate gyrus, *F* = 2.384 for CA1, *F* = 0.574 for CA2/CA3, *F* = 0.935 for subiculum, *F* = 0.633 for inhibitory neurons, *n* = 3 biological replicates per genotype. Statistical analysis done by one-way ANOVA with Holm-Bonferroni *P* value adjustment; boxplots show: middle, median; lower hinge, 25% quantile; upper

hinge, 75% quantile; upper/lower whisker, largest/smallest observation less/greater than or equal to upper/lower hinge  $\pm 1.5 \times$  IQR. **b**, Volcano plots showing differentially regulated genes across genotypes in subiculum, dentate gyrus, CA1, CA2/3 and inhibitory neurons. ANOVA with Holm-Bonferroni *P* value adjustment. Red and blue dots are determined as statistically significant with  $p \leq 0.01$  and  $\log_2$  fold change  $\pm > 0.5$ .



**Extended Data Fig. 7 | Comparing publicly available inflammatory protein and non-protein coding gene signatures of 5x FAD mice to those of APPPS1 mice. a-b.** Comparing published gene signatures of disease-associated microglia (DAM) and homeostatic microglia (green, b) from 5x FAD AD-like mice to respective microglia signatures from APPPS1 AD-like mice generated within this study reveals (blue, b) a substantial overlap. c-e Volcano plots comparing gene

expression from all microglial cells in APPPS1 versus WT mice (c), APPPS1.112b<sup>-/-</sup> vs. WT mice (d) and APPPS1 vs APPPS1.112b<sup>-/-</sup> mice (e). f-g, UMAP feature plots showing non-coding transcripts for *Neat1* (f) and *Pvt1* (g). h-j, Volcano plot comparing APPPS1 vs. WT mice (h), APPPS1 vs. APPPS1.112b<sup>-/-</sup> mice (i) and APPPS1.112b<sup>-/-</sup> vs. WT mice (j) illustrating that the non-coding lncRNA *Neat1* and *Pvt1* were upregulated in both AD-related genotypes.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

**Data collection** snRNA-seq data were generated/collected using Chromium Next GEM Single Cell 3' GEM, Library & Gel Bead Kit v3.1 and sequenced on an Illumina HiSeq 4000 sequencer. Demultiplexing, barcode processing, read alignment and gene expression quantification was carried out using Cell Ranger software (v3.1.0, 10x Genomics). Confocal images were collected using LAS X 3.3 Stage Experiment Tilescan software (Leica) and Nikon Spinning Disk Confocal microscope. EM (ultrastructural) images were taken at LEO912 Electron-Microscope (Zeiss). Lipidomic data were generated using a hybrid quadrupole-Orbitrap mass spectrometer (Q-Exactive, Thermo Fisher Scientific). qPCR was performed on QuantStudio™ 6 Flex (Applied Biosystems). MSD data were generated using a MS6000 machine (MSD).

**Data analysis** Computational data was analyzed in R (v3.6.0) using Seurat (v3.1.2), Scrublet (v0.21), R package stats (v3.6.0), EdgeR (v3.28.1), topGO (v2.36.0), SCORPIUS (v1.0.7), mgcv (v1.8-28), CellPhoneDB (V2.1.1), biomaRt (v2.42.1), Sambamba (v0.6.8), bedtools (v2.27.1), bedGraphToBigWig (v4), GTfTools(v0.6.9). Images were analyzed using Image J (v1.52). Further data analysis were done using GraphPad Prism (v9). Analysis of mass spectrometry data was performed using Compound Discoverer 3.3.2.31 (Thermo Fisher Scientific) and matched to metabolite databases LipidBlast V568 and Metlin Experimental Mass Spectral Database Vers 2017 (Scripps Center for Metabolomics). MetaboAnalyst 6.0 (<https://metaboanalyst.ca>) was used to plot lipidomics data.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The raw sequencing and processed data is available in GEO under the accession GSE173242 and a shiny app was created, which allows to access single-nuclei data for any gene of interest interactively via the following URL: [https://shiny.mdc-berlin.de/AD\\_Neuroinflammation/](https://shiny.mdc-berlin.de/AD_Neuroinflammation/). Lipidomics data for re-analysis are available on Zenodo repository under the DOI: 105281/zenodo.14620944. Source data and immunohistological image files will be provided upon request.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	If data were gained to be used as an exploratory approach, n=3 per genotype was chosen in order to be able to perform basic statistical analyses (snRNA-seq, EM imaging). For biochemical and molecular analyses, n=5 or n=9 were chosen to account for known biological variability. For lipidomics, we used an n of 8 due to the same biological and technical reasons. For immunohistological stainings we used an n of 6 to 8 per genotype and n=3-12 slices depending on the experiment which we have applied from experience in other studies. For cell culture experiments, we have run five independent experiments each with three technical replicates per condition. We have not statistically calculated sample sizes prior to experimental design, but chosen these numbers with our best knowledge.
Data exclusions	For the identification of differentially regulated gene expression in snRNA-seq data, we removed the Ttr gene as its expression was highly dependent on the presence of a Choroid Plexus cluster in a given sample, suggesting a dissection bias at the stage of hippocampus isolation (indicated in the Methods Section). Performing the 6e10 MSD assay on protein extraction generated from brain tissue of APPPS1.NestinCre.II23Rfl/fl animals, a few readings generated the output "NaN" due to technical error. This individual data point as a non-available value was therefore excluded in the subsequent analysis. This is indicated by the fewer data points in Figure 1e.
Replication	Cell culture experiments were repeated with similar outcome in five independent experiments. Stainings and all molecular analyses have not been repeated due to the value of the tissue except for the MBP staining in Fig. 4f to compensate for variability in individual animals, but results are aligned between one another and when comparing young and old animals. We have made sure to approach the different aspects (such as myelination) in as many independent analyses as possible.
Randomization	Animals allocated to experimental groups were based on genotype. No method of randomization has been applied.
Blinding	Investigators were blinded for tissue collection and processing as well as subsequent data collection (e.g., microscopy) and analysis. Additionally, different investigators were involved in different analyses and the data was later combined, resulting in an objective that convinces us of the validity of our results.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging



## Antibodies used

Olig2 (Rabbit, 1:750, AB9610, Millipore), Anti-APC clone CC-1 (Mouse, 1:200, OP80-100UG, Merck), MBP clone 12 (Rat, 1:200, MCA409S, Biorad), Parvalbumin clone PARV-19 (Rabbit, 1:200, MAB1572, Millipore), Clec7a clone R1-8g7 (Rat, 1:150, mapg-mdect, InvivoGen), Iba1 (Rabbit, 1:500, 019-19741, Wako), 4G8 residues 17-24 of A $\beta$  (Mouse, 1:1000, SIG39320, Covance), Alexa568 goat anti rabbit (A11011; 1:300, Invitrogen), Alexa488 goat anti-mouse IgG (A11001; 1:300, Invitrogen), Alexa488 goat anti-mouse IgG2b (A21141, 1:300, Invitrogen), Alexa647 goat anti-rabbit (A21244, 1:300, Invitrogen), Cy3 donkey anti-rat IgG (712-165-153, 1:300, Jackson ImmunoResearch), and Alexa488 goat anti-rat (112-545-003, 1:300, Dianova)

## Validation

Olig2: Evaluated by immunohistochemistry on glioblastoma by vendor. Immunohistochemistry (Paraffin): Representative lot data. Anti-Olig2 (AB9610) staining pattern morphology in glioblastoma. Tissue was pretreated with TE Buffer, pH 9.0. Polyclonal antibody was diluted to 1:500, using IHC-Select<sup>®</sup> Detection with HRP-DAB. Optimal Staining With TE Buffer Epitope Retrieval: Glioblastoma

Anti-APC Antibody, clone CC-1 detects levels of APC proteins & has been published & validated for use in IHC. Immunohistochemistry Analysis: A representative lot from an independent laboratory detected APC in human brain tissue containing multiple schlerosis lesions (Saikali, P. et al. (2007). *J Neurosci.* 27(5):1220-1228.). Immunohistochemistry Analysis: A representative lot from an independent laboratory detected APC in rat spinal cord injury tissue (McTigue, D. M., et al. (2001). *J Neurosci.* 21(10):3392-3400.). Immunohistochemistry Analysis: A 1:5 dilution from a representative lot detected APC in human colorectal cancer tissue, human smooth muscle tissue, and human colon tissue.

MBP clone 12: This product has been reported to work in the following applications: ELISA, immunofluorescence, radioimmunoassays, Western Blotting. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators.

Relvas, J.B. et al. (2001) Expression of dominant-negative and chimeric subunits reveals an essential role for beta1 integrin during myelination. *Curr Biol.* 11: 1039-43.

Parvalbumin clone PARV-19 has been used in immunofluorescence:  
A Ca(2+)-binding protein with numerous roles and uses: parvalbumin in molecular biology and physiology.  
BioEssays : news and reviews in molecular, cellular and developmental biology (2009-03-11)  
Syed Hasan Arif  
PMID19274659

4G8: co-localisation with pFTAA stained amyloid beta plaques (M. Jendrach, unpublished data); no signal in wild type microglia (T. Pugada, unpublished data)  
This antibody is reactive to amino acid residues 17-24 of  $\beta$  amyloid. The epitope lies within amino acids 18-22 of  $\beta$  amyloid (VFFAE). 4G8  $\beta$ -amyloid antibody reacts to abnormally processed isoforms, as well as precursor forms.  
This antibody clone has been reported for use on IHC of free-floating sections in PBS containing 1% Triton incubated with 0.1 M citrate buffer (4).  
Poduslo JF, et al. 2004. *Biochem.* 43:6064. (IHC-F) PubMed  
Forny-Germano L, et al. 2014. *J Neurosci.* 34:13629. (IHC-Other) PubMed  
Vallino Costassa E, et al. 2016. *J Alzheimers Dis.* 51: 875:87. (IHC-P) PubMed  
Chen X, et al. 2013. *Neurobiol Aging.* 34:2370. (ICC) PubMed  
Hatami A, et al. 2016. *J Alzheimers Dis.* 50:517. (IHC-P) PubMed

Iba1: standard antibody to visualize microglia (4732 citations): "Fujifilm Wako's "Anti Iba1, Rabbit (for immunocytochemistry)" (Product Number 019-19741), which allows even microglia processes to be stained by immunohistochemical staining, is used by researchers all over the world as a microglia marker antibody standard."  
Imai, Y., Ibaata, I., Ito, D., Ohsawa, K. & Kohsaka, S.: *Biochemical and biophysical research communications*, 224(3), 855(1996).  
A Novel Geneiba1 in the Major Histocompatibility Complex Class III Region Encoding an EF Hand Protein Expressed in a Monocytic Lineage  
Mori, I., Imai, Y., Kohsaka, S. & Kimura, Y.: *Microbiology and immunology*, 44(8), 729(2000).  
Upregulated expression of Iba1 molecules in the central nervous system of mice in response to neurovirulent influenza A virus infection  
Sasaki, Y., Ohsawa, K., Kanazawa, H., Kohsaka, S. & Imai, Y.: *Biochemical and biophysical research communications*, 286(2), 292(2001).  
Iba1 is an actin-cross-linking protein in macrophages/microglia.  
Zhao, S. et al.: *Cell*, 180(4), 796(2020).  
Cellular and Molecular Probing of Intact Human Organs  
Ahn, J.H. et al.: *Lab. Anim. Res.*, 28(3), 165 (2012).  
Comparison of alpha-synuclein immunoreactivity in the spinal cord between the adult and aged beagle dog  
Ide, T. et al.: *J. Vet. Med. Sci.*, 72(1), 99 (2010).  
Histiocytic Sarcoma in the Brain of a Cat  
Gaige, S. et al.: *Neurotoxicology*, 34, 135(2013).  
c-Fos immunoreactivity in the pig brain following deoxyvalenol intoxication: Focus on NUCB2/nesfatin-1 expressing neurons  
Rodriguez-Callejas, J.D. et al.: *Front. Aging Neurosci.*, 8, 315(2016).  
Evidence of Tau Hyperphosphorylation and Dystrophic Microglia in the Common Marmoset  
Fantin, A. et al.: *Blood*, 116(5), 829(2010).  
Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction

Clec7a: supplier: "binding of Anti-mDectin-1-IgG to mDectin-1 on cells has been validated using flow cytometry". Co-stainings with Iba1 in amyloid beta plaque-associated microglia (manuscript and EMBO Rep 2020 21(3):e48530), no signal in wild type microglia (M. Jendrach, unpublished data)  
clone R1-8g7: This product has been validated for neutralization using cellular assays.  
Binding of Anti-mDectin-1-IgG to mDectin-1 on cells has been validated using flow cytometry.

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

1. Fischer M. et al., 2017. Isoform localization of Dectin-1 regulates the signaling quality of anti-fungal immunity. *Eur J Immunol.* 47(5):848-859.
2. Hou H. et al., 2017. C-type Lectin Receptor: Old Friend and New Player. *Med Chem.* 13(6):536-543.
3. Drummond RA. & Lionakis MS., 2016. Mechanistic Insights into the Role of C-Type Lectin Receptor/ CARD9 Signaling in Human Antifungal Immunity. *Front Cell Infect Microbiol.* 6:39.
4. Romero MM. et al., 2016. Reactive oxygen species production by human dendritic cells involves TLR2 and dectin-1 and is essential for efficient immune response against Mycobacteria. *Cell Microbiol.* 18(6):875-86.

beta-Actin: standard antibody to visualize Actin (4100 citations); no staining of mouse heart tissue (M. Jendrach, unpublished data)

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	The human oligodendrogloma cell line (SCC163, Sigma)
Authentication	Directly obtained from vendor (Sigma), therefore only tested within our experimental set-up (regular control experiments, see respective figure).
Mycoplasma contamination	The cell line was not tested for mycoplasma contamination.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No commonly misidentified cell lines were used in this study.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	Mus musculus, C57BL/6. Mice for snRNA-seq study: male, 250-day-old. Mice for immunohistochemistry, EM imaging, biochemical and molecular analysis: 120 and 250-day-old, mixed sexes. APPPS1.NestinCre.II12Rb2fl/fl: 250 day old. Mice for Mesoscale analysis. Mixed sexes. APPPS1.NestinCre.II23Rfl/fl: 250-day-old. Mice for Mesoscale analysis. Mixed sexes. APPPS1.II12b: 120 and 250-day-old, mixed sexes, used for lipidomics, electronmicroscopy, immunohistochemistry. C57BL/6: E13, used for myelinating cell culture experiments. C57BL/6: P3 used for MACS-sorting of oligodendrocytes.
Wild animals	This study did not involve wild animals.
Field-collected samples	This study did not involve samples collected from the field.
Ethics oversight	All animal experiments were conducted in accordance with animal welfare acts and were approved by the regional office for health and social service in Berlin (LaGeSo; license O 298/17, T 0276/07 and T-CH0022/23)

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	Postmortem tissue was collected from participants with neurological diseases as indicated, based on a written informed
Recruitment	Subjects recruited provided written informed consent prior to death.
Ethics oversight	Human tissue sampling, processing and subsequent analyses were done on the basis to the ethical approval Nr. EA1/144/13 granted by the Ethics Board of the Charité – Universitätsmedizin Berlin, Germany. Postmortem brain tissue from the University of Florida Human Brain and Tissue Bank (UF HBTB) was collected with approval from the University of Florida Institutional Review Board (IRB201600067). All the patients or their next-of-kin gave written informed consent for the brain donation and use of tissue specimens for research.

Note that full information on the approval of the study protocol must also be provided in the manuscript.